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Abstract 
Lotta Siira, Clonality of Streptococcus pneumoniae in relation to antimicrobial 
resistance in Finland. National Institute for Health and Welfare. Research 119. ??? 
pages. Helsinki, Finland 2014. 
ISBN 978-952-302-076-4 (printed); ISBN 978-952-302-077-1 (online publication) 
 
Streptococcus pneumoniae, or the pneumococcus, is a bacterium of the human 
normal flora that also causes non-invasive respiratory tract infections, and serious 
infections, such as pneumonia, septicaemia, and meningitis. Globally, the rise in 
pneumococcal antimicrobial resistance is a worrying trend. Over 90 pneumococcal 
capsules are recognised by serotyping; the most important serotypes are included in 
the available vaccines. The 10-valent conjugate vaccine has been part of the Finnish 
national vaccination programme since September 2010.  
 
In this study, the serotype and genotype clonality of the invasive pneumococcal 
population in Finland was studied in relation to antimicrobial resistance. All 
invasive pneumococci isolated in Finland during 2002-2011 and a subset of non-
invasive multidrug-resistant isolates from 2008 were serotyped and studied for 
antimicrobial susceptibility. The penicillin-resistant isolates were genotyped and 
pilus-encoding virulence genes were detected. A sequential multiplex PCR assay for 
serotyping was set up, tailored to the serotype distribution in Finland. 
 
Serotype 14 was the predominant serotype, representing 17.5% of all invasive 
isolates. The proportion of isolates non-susceptible to penicillin and erythromycin 
was high, and it increased over the study period, reaching 22% and 26% for 
penicillin and erythromycin, respectively. The proportion of non-susceptible isolates 
was particularly high among isolates from children and in serotype 14. Among the 
genotyped isolates, international resistant clones dominated, but novel genotypes 
were also found, illustrating the continuous recombination of resistant pneumococci. 
The results of this study showed that in Finland a globally described multidrug-
resistant serotype 19A clone appeared prior to large-scale vaccination. Conversely, 
in many countries, this clone has emerged following vaccination. Pilus-encoding 
gene carriage was frequent among the penicillin- and multidrug-resistant isolates. In 
the future, a vaccine targeting the pilus proteins would most likely be successful in 
controlling these clones. The new serotyping scheme is useful in surveillance, as 
knowledge of the serotype distribution of the invasive pneumococci is essential for 
vaccine development and monitoring of the vaccination programme.  
 
Keywords: Streptococcus pneumoniae, clonality, serotyping, genotyping, 
antimicrobial susceptibility 
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Tiivistelmä 
Lotta Siira, Clonality of Streptococcus pneumoniae in relation to antimicrobial 
resistance in Finland. [Streptococcus pneumoniae -bakteerin klonaalisuus suhteessa 
lääkeherkkyyteen Suomessa]. Terveyden ja hyvinvoinnin laitos. Tutkimus 119. 
157 sivua. Helsinki, Finland 2014. 
ISBN 978-952-302-076-4 (painettu); ISBN 978-952-302-077-1 (verkkojulkaisu) 
 
Streptococcus pneumoniae, pneumokokki, on normaaliflooran bakteeri, joka voi 
aiheuttaa hengitystieinfektioita sekä vakavia tauteja, kuten keuhkokuumetta, 
verenmyrkytyksiä ja aivokalvontulehdusta. Pneumokokkien mikrobilääkeresistenssi 
on maailmanlaajuisesti ollut huolestuttavassa kasvussa. Pneumokokilla tunnetaan yli 
90 eri polysakkaridikapselia, jotka määritetään serotyypittämällä. Käytössä olevat 
rokotteet kattavat tärkeimmät serotyypit. 10-valenttinen pneumokokki-
konjugaattirokote on syyskuusta 2010 lähtien ollut osa kansallista rokotusohjelmaa. 
 
Tässä tutkimuksessa tarkasteltiin invasiivisten pneumokokkien klonaalisuutta sekä 
serotyyppi- että genotyyppitasolla suhteessa mikrobilääkeherkkyyteen. Serotyyppi ja 
mikrobilääkeherkkyys määritettiin kaikille Suomessa vuosina 2002-2011 eristetyille 
invasiivisille kannoille sekä osalle vuonna 2008 eristetyille ei-invasiivisille moni-
resistenteille pneumokokeille. Penisilliiniresistenteille kannoille määritettiin lisäksi 
genotyyppi ja pilusgeenien läsnäolo. Lisäksi pystytettiin Suomen pneumokokki-
populaatioon räätälöity multiplex-PCR -pohjainen serotyypitysmenetelmä. 
 
Serotyyppi 14 oli tärkein, se kattoi 17,5 % kaikista tutkimuksen invasiivisista 
pneumokokeista. Penisilliinille ja erytromysiinille herkkyydeltään alentuneiden 
kantojen osuudet olivat korkeat ja kasvoivat tutkimusjaksona kattamaan yli 
viidenneksen kannoista. Herkkyydeltään alentuneiden kantojen osuus oli erityisen 
korkea lapsilta eristettyjen kantojen keskuudessa sekä serotyypillä 14. 
Genotyypitetyt kannat olivat sukua maailmanlaajuisille resistenteille pneumokokki-
klooneille. Myös uusia genotyyppejä havaittiin, mikä kuvastaa resistenttien kloonien 
jatkuvaa kehitystä. Havaittiin, että serotyypin 19A moniresistentti klooni on 
esiintynyt Suomessa jo ennen laajamittaisia rokotuksia, vaikka se on useassa maassa 
yleistynyt vasta rokotusten myötä. Valtaosa tutkituista resistenteistä kannoista kantoi 
pilusgeenejä. On todennäköistä, että mahdollinen pilusproteiineja sisältävä rokote 
kykenisi tulevaisuudessa torjumaan näitä kantoja. Pystytetyllä serotyypitys-
menetelmällä voidaan selvittää invasiivisen pneumokokkipopulaation serotyyppi-
jakauma. Sen tunteminen on ensiarvoisen tärkeää rokoteseurannassa ja rokote-
kehittämistyössä. 
 
Avainsanat: Streptococcus pneumoniae, klonaalisuus, serotyypitys, genotyypitys, 
mikrobilääkeherkkyys 
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Sammandrag 
Lotta Siira, Clonality of Streptococcus pneumoniae in relation to antimicrobial 
resistance in Finland. Institutet för hälsa och välfärd. [Streptococcus pneumoniae-
bakteriens klonalitet i relation till antibiotikaresistens i Finland]. Forskning 119. 
157 sidor. Helsingfors, Finland 2014. 
ISBN 978-952-302-076-4 (tryckt); ISBN 978-952-302-077-1 (nätpublikation) 
 
Streptococcus pneumoniae, eller pneumokocken, är en bakterie som finns i 
människans normalflora men också orsakar allt från milda luftvägsinfektioner till 
svåra invasiva sjukdomar som lunginflammationer, sepsis och hjärnhinne-
inflammationer. Globalt sett har antibiotikaresistensen bland pneumokocker ökat 
oroväckande under de senaste decennierna. Fler än 90 olika polysackaridkapslar har 
beskrivits; dessa bestäms genom serotypning. De viktigaste serotyperna finns med i 
de vaccin som utvecklats mot pneumokocksjukdomar. I september 2010 blev det 10-
valenta konjugatvaccinet en del av det nationella vaccinationsprogrammet i Finland. 
 
I den här undersökningen granskades de invasiva pneumokockernas klonalitet både 
på sero- och genotypnivå i förhållande till antibiotikaresistensen i Finland. Serotyper 
och antibiotikakänslighet bestämdes för alla invasiva pneumokocker som isolerades 
i Finland under åren 2002-2011 och för ett sampel av multiresistenta icke-invasiva 
pneumokocker från år 2008. De penicillinresistenta stammarna genotypades och 
deras gener för piluskodande virulensfaktorer utreddes. Ett nytt serotypnings-
protokoll baserat på multiplex-PCR sattes också upp. 
 
Bland serotyperna var serotyp 14 den viktigaste, den utgjorde 17,5% av alla invasiva 
stammar. Andelen isolat med nedsatt känslighet mot penicillin eller erytromycin var 
hög och ökade under forskningsperioden till 22 %, respektive 26 %, av stammarna. 
Andelen stammar med nedsatt antibiotikakänslighet var speciellt hög bland isolat 
från barn och inom serotyp 14. Internationella resistenta kloner dominerade bland de 
genotypade stammarna. Nya genotyper hittades också vilket beskriver de resistenta 
klonernas fortsatta utveckling. Resultaten visar också att den multiresistenta serotyp 
19A-klon som på många håll i världen ökat markant efter vaccinering, hade fått 
fotfäste i Finland redan före storskalig vaccinering inletts. Majoriteten av de 
penicillin- och multiresistenta pneumokockerna bar på piluskodande gener, vilket 
tyder på att ett vaccin som innehåller pilusprotein i framtiden kunde begränsa dessa 
viktiga kloners framfart. Det nya serotypningsprotokollet möjliggör också i 
fortsättningen granskningen av pneumokockernas serotypfördelning för vaccin-
uppföljning och vaccinutvecklingsbehov. 
 
Nyckelord: Streptococcus pneumoniae, klonalitet, serotypning, genotypning, 
antibiotikaresistens 
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1 Introduction 
Streptococcus pneumoniae, or the pneumococcus, is a commensal bacterium, which 
also causes infections of the upper respiratory tract and serious infections such as 
meningitis, septicaemia, and pneumonia. According to the Finnish National 
Infectious Disease Register, more than 700 invasive pneumococcal infections are 
diagnosed annually. The pneumococcus is asymptomatically carried in the 
nasopharynx especially by young children, with carriage rates decreasing with 
increasing age. Carriage is essential for disease to develop, and the strain causing 
disease tends to originate from the nasopharynx of the patient. The pneumococcus 
engages in both inter- and intraspecies competition in its natural habitat. 
 
The pneumococcus is a diplococcus that is alpha-haemolytic when cultivated on 
blood agar. A capsule made of polysaccharides covers the bacterial cell and enables 
the bacterium to evade the immune system and is an important virulence factor. To 
date, more than 90 different capsular types, or serotypes, have been described. These 
differ in both immunogenicity and virulence and often, but not always, represent 
diverse genetic backgrounds. The most frequently occurring serotypes causing 
invasive disease are included in the available vaccines. The 10-valent pneumococcal 
conjugate vaccine is included in the Finnish national vaccination programme as of 
September 2010. The large-scale use of vaccines will assert serotype selection 
pressure that is likely to bring about changes both on the serotype and genotype 
level within the pneumococcal population. Over the last few decades, pneumococcal 
resistance to commonly used antimicrobial drugs has emerged. This is a worrying 
trend posing new treatment challenges. 
 
The aim of this study was to examine the clonality of the invasive pneumococcal 
population, both on the serotype and the genotype level, and to set up a serotyping 
scheme tailored to study the invasive pneumococcal isolates in Finland. The study 
also examined a subset of multidrug-resistant non-invasive isolates that have 
increasingly been encountered. From a surveillance standpoint, these isolates are 
important, because changes in the non-invasive population are usually reflected in 
the invasive bacterial population in time. By combining virulence factor and clonal 
analysis the results of this study may be useful when future prevention strategies are 
considered and developed. 
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2 Review of the literature 
2.1 The “sugar-coated microbe” and breakthroughs in the life 
sciences 
Streptococcus pneumoniae, or the pneumococcus, is a Gram-positive, facultatively 
anaerobic catalase-negative round or lancet shaped diplococcus. It is fairly 
demanding to cultivate in the laboratory and generally thrives best in an atmosphere 
enriched with carbon dioxide. When cultivated on blood agar, it produces greenish 
alpha-haemolysis, as the hydrogen peroxide of the bacteria oxidises haemoglobin. 
The colonies are round and often dented in the middle, but the appearance depends 
on the capsular type, as some serotypes have a mucoid appearance. The bacterial cell 
is covered by a polysaccharide capsule, the structure of which determines the 
serotype of the bacterium. The capsule is an important virulence factor [3, 160].  
 
The history of pneumococcal research mirrors the history of key findings and 
milestones in bacteriology and the life sciences. After the development of a light 
microscope with sufficiently high resolution to reveal bacteria that the naked eye 
could not detect, coccoid bacteria in pairs found in pulmonary tissues were reported 
in the literature in 1875 [111]. In 1881, the pneumococcus was described as a 
pathogen after it had been isolated independently by two researchers, George M. 
Sternberg and Louis Pasteur [11, 325]. Both found diplococcoid bacteria in the 
saliva of human carriers and both went on to inject the saliva into rabbits, thereby 
causing disease, and were able to recover the bacteria from the rabbit blood [325]. 
Since its discovery, the pneumococcus has been renamed several times. Its initial 
names Microbe septicemique du salive given by Pasteur and Micrococcus pasteuri 
by Sternberg, gave way to Pneumococcus a few years later, when its predisposition 
to cause respiratory tract disease became clear. In 1920, it went on to officially carry 
the name Diplococcus pneumoniae, given in an effort to describe both the shape and 
clinical manifestation of the bacterium. In 1974, the current name, Streptococcus 
pneumoniae, was adopted to indicate that in liquid media the bacteria grow in chains 
like other members of the Streptococcus genus. The pneumococcus was one of the 
first bacteria to be Gram-stained, a procedure developed by Hans Christian Gram in 
the 1880s and still relevant today in identifying clinically significant bacteria [325]. 
 
In 1923, the discovery that the pneumococcal capsule was comprised of 
polysaccharides, i.e. sugar, caused a stir. Until then, it had been widely accepted that 
only proteins were capable of acting as antigens and causing an immune response 
[296, 325]. Physician Oswald Avery, who was active in pneumococcal research for 
Review of the literature 
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several decades, affectionately called the pneumococcus the “sugar-coated microbe” [17]. 
Research into the pneumococcal capsule established it as a major virulence factor when 
it was discovered that it protects the bacterium from opsonisation and phagocytosis by 
the immune system. This research, in turn, developed into the demonstration of the 
microscopically visible Quellung reaction, in which the capsule swells upon addition of 
specific antiserum to pneumococci in liquid media (Figure 1) [12, 325]. This reaction is 
still commonly known by the German word for swelling, Quellung, or as the capsular 
reaction test, and is widely used for serotyping pneumococci. The number of known 
pneumococcal serotypes increased from two in 1910 to 85 some fifty years later [325]. 
Today, more than 90 different serotypes are known [23]. 
 
 
Figure 1. A positive Quellung reaction as seen in a phase contrast microscope. 
 
Chemotherapy against pneumococcal infections, one of the first uses of specific 
antimicrobial agents as therapy for bacterial infections, took place as early as 1911. 
The agent in question was the quinine derivative ethylhydrocuperine, known as 
optochin, which specifically inhibits growth of pneumococci. Its therapeutic use was 
abandoned because of toxicity and rapidly developing resistance, but in the 
laboratory optochin remains a reliable tool for distinguishing pneumococci from 
other closely related species [33, 111]. The first successful use of penicillin in a 
clinical setting was against a pneumococcal conjunctivitis infection, establishing the 
clinical and therapeutic usefulness of the drug [325]. When penicillin was launched 
in the 1940s, it became the drug of choice and its use dramatically reduced mortality 
of serious pneumococcal infections [111]. 
 
The significance of breakthroughs made in pneumococcal research extends far 
beyond bacteriology. The best example of this is the discovery of deoxyribonucleic 
acid (DNA) as the hereditary molecule [14, 296]. This discovery made in 1944 built 
Review of the literature 
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upon the work from previous decades, when researchers had discovered that rather 
than being stable, an avirulent non-capsulated pneumococcus could become virulent 
when injected into a mouse simultaneously with heat-killed bacteria of a virulent 
capsulated strain [113]. This transformation of material that changed the phenotype 
of the strains in a so-called capsular switching event was shown to occur in liquid 
media as well as in laboratory animals. The chemical properties of the transforming 
molecule were consistent with those of DNA, although until then, it had been 
generally believed that protein was the genetic material. The finding was so ground-
breaking that it took nearly a decade before it was widely accepted in the scientific 
community that DNA was the hereditary molecule and contained the genes of the 
organisms [201, 296]. 
 
2.2 Pneumococcal disease and carriage 
In 2005, the World Health Organization (WHO) estimated that 1.6 million deaths 
annually were caused by the pneumococcus. Children under the age of 5 years 
account for 0.7–1 million of these deaths, and developing countries are most 
severely affected [333]. In 2008, it was estimated that 476,000 deaths in young 
children were caused by pneumococcal infections [332]. In developed countries, the 
pneumococcus is a common cause of community-acquired pneumonia in adults, 
sometimes accompanied by bacteraemia [29, 176]. In Europe, the age-standardised 
incidence of invasive pneumococcal disease was 5.12 per 100,000 population in 
2010, according to the European Centre for Disease Prevention and Control (ECDC) 
[92]. However, the incidences show great variation between countries; in the years 
2002 to 2005, they were 0.4 to 25.8 per 100,000 population [270]. In the Nordic 
countries, the age-standardised incidence per 100,000 population in the year 2010 
was 14.82 in Sweden, 15.08 in Finland, 16.18 in Norway, and 17.26 in Denmark, 
respectively [92, 246]. In Finland, the incidences of both laboratory confirmed 
bloodstream infections as a whole, and invasive pneumococcal infections have 
increased over the past few decades [287, 300]. In 2012, 752 cases of invasive 
pneumococcal infections were registered in the National Infectious Disease Register 
(NIDR) [300]. In Finland, the incidence of pneumococcal bloodstream infections is 
slightly higher among males than females and the case fatality rate within a month is 
10%. Nearly half of the deaths occur within two days of a positive blood culture 
sample [286]. The invasive pneumococcal disease incidence displays seasonal 
fluctuation, increasing in the winter months and correlating with the findings of 
influenza and other respiratory viruses [105, 298]. In Finland, a temporal association 
between invasive pneumococcal disease in young children and peaks in rhinovirus 
circulation during spring and autumn has been established [247]. Regional and 
ethnic differences have also been described in the incidence of invasive 
pneumococcal disease [189]. 
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Figure 2. Pneumococcal colonisation and disease. Drawing by Hanna Siira. 
 
The distribution of the clinical spectrum of pneumococcal colonisation and disease 
can be likened to an iceberg (Figure 2). Under the surface, the widest part is made 
up of colonisation; this is the most common situation, where the pneumococcus acts 
as a commensal. The visible part of the iceberg represents the clinical cases. The 
majority of these are non-invasive, relatively mild conditions, such as otitis media 
common in children, and other respiratory infections. Above are pneumonia and 
other serious conditions, and at the very top of the iceberg are bloodstream-
infections, and finally, meningitis [160, 189]. 
 
Most pneumococcal disease cases are sporadic and transmission takes place from 
person to person though droplets or aerosols [134, 160]. Although rare and usually 
limited in size, invasive and non-invasive outbreaks have been described in confined 
settings such as nursing homes, hospital wards, day care centres, military camps, and 
homeless shelters [27, 104, 114, 143, 264, 309]. In the so-called meningitis belt in 
Africa, invasive outbreaks associated with serotype 1 have occurred [178, 225], and 
serotype 15F strains has been found to cause outbreaks in rural communities in 
Alaska [347]. 
 
Host risk factors for pneumococcal carriage and disease include alcohol abuse, 
smoking or exposure to tobacco smoke, asthma, and acute upper respiratory 
infections [189]. Day care or school attendance and more than four co-habitants are 
risk factors for invasive pneumococcal disease in children [52, 53]. Human 
immunodeficiency virus infections and the acquired immunodeficiency syndrome 
are predisposing conditions to pneumococcal disease, as is any other 
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immunocompromising condition and old age [189, 322]. Young children are also 
susceptible to pneumococcal disease mainly because their immune systems have yet 
to fully develop and therefore are not able to quickly eradicate polysaccharide 
covered pneumococci [332]. The factors of and interplay between both the 
bacterium and the human host determine whether the pneumococcus is able to cause 
disease, as well as the severity and clinical manifestation of the disease. Disease is a 
relatively rare event compared to carriage. Upon acquisition, a strain may be carried 
for weeks or even months in the nasopharynx, where both innate and adaptive 
immune responses are involved in limiting the pneumococci [135, 160]. In carriage, 
the pneumococcus adheres to the resting epithelial lining of the nasopharynx. For 
disease to develop, the bacterium must spread from the nasopharynx, either locally 
when causing sinusitis or otitis media, by aspiration into the alveoli when causing 
pneumonia, or by invading the bloodstream when causing septicaemia. In meningitis, 
the brain-blood barrier is breached and the pneumococci reach the cerebrospinal 
fluid [31]. 
 
The carriage rate is high during the first two years of life and declines thereafter. In 
healthy 18-month-old children in a study conducted in the Netherlands it was 12% 
[30], while it was as high as 55.5% in children below 24 months in a study from the 
UK [245], 49.3% in 4 to 12-month-old children in Bangladesh [109], and 9-43%, 
increasing with age, in 2 to 24-month-old healthy children in a Finnish study [297]. 
Age-related decline in pneumococcal carriage is caused by the maturation of the 
immune system and occurs parallel with simultaneous increase in Staphylococcus 
aureus carriage [32]. The nasopharynx of children can be considered the natural 
habitat of the bacterium and the reservoir from where it may be transmitted. Adults 
in families with young children are often more likely to carry the bacterium than 
their peers living in families without children. The adult carriage rate varies in 
different populations and in different settings but is often below 10% [134]. 
 
The pneumococcus has sporadically been encountered in pets, as well as zoo and 
laboratory animals [314], but humans are its main host. Nasopharyngeal colonisation 
is a dynamic process, in which carried species and serotypes are in flux and vary by 
age, season, geographical area, genetic background, and is further influenced by 
socioeconomic factors. Interventions, such as the use of antimicrobial agents and 
vaccines, also have an impact on the dynamic [30-32]. The pneumococci found in 
carriage and non-invasive samples are more diverse than the strains most commonly 
isolated from invasive samples [121, 175]. The pneumococcus has a complex 
relationship with the estimated 700 other bacterial species that share this niche [160]. 
The resident bacterial flora, which includes alpha-haemolytic species, inhibits the 
colonisation of invading species, such as pneumococci, Haemophilus influenzae, and 
Moraxella catarrhalis. Furthermore, several of the pathogens have competitive 
relationships with the other species [31]. The pneumococcus can interfere with the 
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growth of S. aureus, M. catarrhalis, H. influenzae, and the meningococcus Neisseria 
meningitidis [31, 32, 248]. On the other hand, meningococcal presence in vitro 
increases the growth of pneumococci [31]. 
 
2.3 Pneumococcal virulence factors 
The pneumococcus is able to adapt its gene expression in a site specific manner and 
its different virulence factors play varyingly important roles depending on the strain, 
as well as on the type and stage of disease, as [160, 239]. The most important 
virulence factor of the pneumococcus is the polysaccharide capsule [192], which is 
discussed in detail in the next section. However, the bacterium also has other 
virulence factors that facilitate colonisation and survival in the host; some of the 
most central are discussed below. 
 
The exotoxin pneumolysin is expressed by nearly all invasive pneumococcal isolates, 
and several different variants of the molecule are known [160]. Pneumolysin is 
cytolytic at high concentrations, when the soluble proteins oligomerise in the 
cholesterol-containing membranes of the target cells to form large round pores 
consisting of more than 40 subunits [305]. At lower concentrations, pneumolysin is 
cytotoxic and interferes with the immune defence by influencing ciliary beating, 
complement activation, and induction of intracellular oxygen radicals [160, 198]. 
The role of pneumolysin in pneumococcal virulence in pneumonia is well 
established. It also seems to be important in the survival and spread of bacterial from 
the lungs to the bloodstream and for the clinical manifestation of bacteraemic 
infections [161, 238]. Its role in meningitis remains controversial [160]. 
 
Several protein structures that influence virulence are located on the surface of the 
pneumococcal cell. The most recently discovered are pili, hair-like adhesive 
structures that protrude from the bacterial surface [73, 230]. The pneumococcal pili 
are encoded by two pilus islets, PI-1 and PI-2, on the bacterial chromosome. These 
were revealed by whole-genome sequencing. Clinical and carriage isolates may 
carry none, one, or both of the islets [1]. The expression of PI-1 has been shown to 
mediate adhesion to host cells and provide a competitive advantage in an animal 
model of respiratory tract colonisation [18, 230]. Initially, this pathogenicity islet 
was named rlrA islet, after its positive regulator gene. Pneumococcal PI-1 carriage is 
associated with antimicrobial non-susceptibility [2]. The presence of PI-1 is a clonal 
property, with a stronger association with the genotype than the serotype [2, 223]. 
Expression of PI-2 also mediates adherence to host cells [16]. In contrast to PI-1, PI-
2 is associated with antimicrobial susceptibility, although dual carriage of PI-1 and 
PI-2 is associated with antimicrobial resistance [1, 343].  
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On its surface, the pneumococcus also carries several choline-binding proteins that 
interact with host structures and influence virulence. The proteins are anchored by 
their homologous C-terminal parts to the pneumococcal cell wall phosporylcholine 
and vary in their protruding parts [118]. One of the choline-binding proteins is the 
pneumococcal surface protein A (PspA), a variable molecule that prevents 
complement mediated killing of the bacteria [141, 160]. Another is the 
pneumococcal surface protein C (PspC), also known as choline-binding protein A, 
which helps the bacteria adhere to epithelial cells and promotes nasopharyngeal 
colonisation [160]. 
 
After reaching the stationary phase in the growth curve, the pneumococcus 
undergoes characteristic autolysis by degrading its cell wall and thereby inducing its 
own death. This trait seems to add to virulence and protect intact bacteria from 
clearing by the immune system [196, 198, 336]. The major autolysis inducing 
enzyme autolysin (LytA), or N-acetylmuromyl-L-alanine amidase, severs bonds in 
the peptidoglycan cell wall [160]. Several theories of why LytA influences virulence 
have been suggested: its induction releases other virulence factors or toxins for 
instance pneumolysin and the cell wall components, and its induction may hinder 
phagocyte activities [160, 198]. Together with pneumolysin, LytA is essential for 
the survival of the pneumococcus in the bloodstream [238]. 
 
Pneumococcal surface adhesin (PsaA) is a lipoprotein located at the bacterial cell 
wall that appears to be involved in providing resistance to oxidative stress [160]. 
Teichoic acid and peptidoglycan, both major cell wall components, induce 
inflammation [307], while other pneumococcal virulence factors include LPXTG-
anchored proteins such as neuraminidases and pneumococcal histidine triad proteins 
[118]. 
 
2.4 The pneumococcal capsule 
The capsule is the most important virulence factor for invasive pneumococcal 
disease [160, 192]. The capsule inhibits complement and protects the bacterial cell 
from neutrophil-mediated killing, while the protection increases with the degree of 
encapsulation [160, 329]. Strains with a thick capsule are more virulent and prone to 
cause invasive disease, while strains with a thinner capsule are more often found in 
asymptomatic carriage [340].  
 
More than 90 different pneumococcal serotypes have been described to date, but a 
smaller number is responsible for most invasive disease. Globally, more than 80% of 
invasive disease is caused by around 20 serotypes [158, 333]. The serotype 
distribution of the invasive pneumococci varies depending on time, place, and age-
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group [126, 127, 284]. Fluctuations in the serotype frequencies or proportions may 
take place over time even without selection pressure asserted by interventions [99, 
122]. In children under 5 years of age, serotype 14 is the most common cause of 
invasive pneumococcal disease in all regions. Often it is an important cause of 
invasive disease in other age-groups as well [126, 158]. The serotypes differ in 
genetic, immunological, biochemical, and epidemiological properties [23, 277]. 
Indeed, they show such variation in their properties, epidemiology, and invasive 
disease outcomes, that from an epidemiologic point of view, it has been suggested 
that each of them should be considered a separate pathogen [127, 328]. The risk 
factors, disease focus, and clinical presentation are partly associated with serotype 
[53, 284, 315, 347], and carriage efficiency also depends on the capsule [125]. 
 
Certain serotypes or serogroups display high invasive disease potential, i.e. they 
exhibit a high propensity for causing invasive disease relative to the exposure 
through carriage, while others show low invasive disease potential, i.e. they are 
common in carriage but proportionately rarer in invasive disease episodes. These 
serotypes or serogroups are summarised in Table 1. As illustrated, the invasive 
disease potential of some serotypes, such as serotype 3, exhibit differences between 
studies. Interestingly, high invasive disease potential has not been linked to high 
mortality [285], but serotypes 3, 6A, 6B, 9N, 11A, 19F, and 31 are associated with 
increased risk of death [285, 315, 328]. Underlying conditions allow serotypes with 
otherwise low invasive disease potential to act as opportunistic pathogens and cause 
invasive disease [285]. Just as the capsule affects the pathogenesis of a 
pneumococcal strain, non-encapsulated isolates also display particular 
characteristics and appear to have a propensity to cause conjunctivitis [119]. 
 
Table 1. Serotypes or serogroups with high or low invasive disease potential, respectively, as 
identified in three studies. 
Serotypes/groups with high invasive 
disease potential 
Serotypes/groups with low invasive 
disease potential 
Reference 
1, 5, and 7 3, 6A, and 15 [38] 
6B, 14, 18C, and 19A 6A and 11A [121] 
3, 7F, 18C, 19A, 22F, and 33F 6C, 11A, 15A, 15B/C, 19F, 23A, 35B, 
and 35F  
[339] 
 
To date, 97 different pneumococcal serotypes or capsular types belonging to 46 
serogroups have been published [23, 34, 42, 43, 132, 164, 237, 244, 345]. In 
addition to these serotypes, the DNA sequence of a novel serogroup 33 subtype, 
proposed to be named 33E, is available in the nucleotide sequence database 
(accession numbers EU071709 and EU071709 [302]). Currently, not all of the most 
recently described serotypes are distinguishable by conventional antisera [42, 164, 
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275]. As both genetic and immunologic methods for studying pneumococcal 
serotypes evolve, it is likely that new serotypes or further structural subtypes of 
previously described serotypes are discovered [85, 203, 275]. 
2.4.1 Capsular genes, structure, and production 
The capsule is the outermost layer of the pneumococcal cell. Its thickness is 200 to 
400 nm and varies considerably depending on the serotype [288]. The structure of 
the capsular polysaccharides varies depending on the serotype and may be linear or 
branched. Branching is determined by the enzymes catalysing the polymerisation of 
the polysaccharide [340]. The structure of the capsular polysaccharides also affects 
the prevalence of the serotype in carriage [329]. 
 
All but two of the pneumococcal capsular polysaccharides are synthesised and 
transferred to the cell surface through the so-called wzy pathway. This pathway is 
also used in some Gram-negative bacteria and in nearly all other Gram-positive 
bacteria for capsular synthesis [340]. The proteins required for the wzy pathway are 
encoded by genes located in the capsule polysaccharide synthesis locus cps, which 
can be found between dexB and aliA on the pneumococcal chromosome (Figure 3). 
The locus varies in size from 10,337 bp for serotype 3, to 30,298 bp for serotype 38, 
depending on the specific genes required for the synthesis of each serotype [23]. 
Within the locus, the genes were originally named cps to which a letter was added 
for each individual gene in the sequence, i.e. cpsA, cpsB, cpsC, cpsD etc. More 
recently, the cps genes have been re-named by function and orthology. This allows 
homologous genes in different serotypes and across different species to carry the 
same name regardless of their relative location within cps. The aforementioned four 
genes are named wzg, wzh, wzd, and wze in most serotypes (Figure 3) [23, 156, 340]. 
At the 5’ region, the cps locus contains the four conserved genes, which are involved 
in the modulation of the capsular synthesis [156, 340]. In one study, expression of 
the regulatory gene wzg (cpsA) correlated inversely with the thickness of the capsule 
[125]. Located downstream from the conserved genes are the serotype specific genes 
that encode enzymes for carrying out the polymer-specific tasks. In most serotypes, 
these enzymes consist of glycosyltransferases, polymerases, flippases, transferases, 
nucleotide dephospho-sugar synthases, and modification enzymes, such as O-
acetylases [340]. 
 
Sugars needed for polysaccharide assembly are synthesised in the cytoplasm of the 
bacterial cell by housekeeping genes or cps-encoded genes, depending on the 
serotype [340]. The hypothetical biosynthesis of the capsule has been described as 
follows. The first transferase, WchA, links the initial sugar to a membrane-
associated lipid carrier on the inside of the cytoplasmic membrane. Further glycosyl 
transferases sequentially link sugars to form a repeat unit, which upon completion is 
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transported across the cytoplasmic membrane by the Wzx flippase. The Wzy 
polymerase attaches individual repeat units to form lipid-linked capsular 
polysaccharides. The Wzd/Wze complex located in the cytoplasmic membrane and 
the inner wall zone translocates the mature polysaccharides and may also be 
responsible for their attachment to the peptidoglycan surface (Figure 3) [23]. 
 
The only two capsular types, serotypes 3 and 37, which are not synthesised by the 
wzy pathway, are produced using the synthase dependent pathway [186, 340]. This 
pathway involves fewer genes than the wzy pathway and the capsular 
polysaccharides are simpler. The cps of the serotype 3 capsule is located between 
dexB and aliA, just as the wzy pathway genes, although the conserved genes are non-
functional [10]. In serotype 37, this locus is occupied by a defect 33F-like sequence 
and the single tts gene required for capsular synthesis is located elsewhere on the 
chromosome [186, 340]. 
 
Pneumococci carrying and expressing more than the genes for one capsule following 
transformation experiments have been described. However, not only are these kinds 
of isolates extremely rare, but they are also unstable [13, 26]. The cps locus displays 
heterogeneity and in some cases the difference between serotypes can arise from a 
difference in a single nucleotide position. For example, in serotypes 6A and 6B a 
single nucleotide polymorphism in the rhamnosyl-transferase gene wciP changes the 
amino acid in position 195 from serine in 6A to asparagine in 6B. This accounts for 
the difference between the two capsules [200]. That changes in the cps locus affect 
the capsular production is also illustrated in the two types of spontaneous phase 
variation exhibited by the pneumococcus, both of which at least partly involve the 
capsule. Firstly, the colony morphology can switch from a thickly encapsulated 
opaque to a thinly encapsulated transparent form. This may have implications for 
colonisation, as the transparent form exhibits higher colonisation rates in animal 
models, while a thicker capsule adds to virulence. The exact mechanism of 
switching from the transparent to opaque form is not fully known [321]. Secondly, 
the other type of phase variation, which involves switching on and off the capsular 
production in a single strain, has been observed in the laboratory for serotypes 3, 8, 
and 37 [323, 324]. Furthermore, serotypes 15B and 15C can interchange from one to 
the other at a frequency of up to 1 in 250 by the mechanism of slipped-strand 
mispairing in a tandem repeat sequence within one of the cps genes [316]. 
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Regulation of capsule expression probably takes place both at the transcription and 
post-transcription level. The cps affects the growth curve of the strain in the 
laboratory, as the capsules differ in metabolic burden. The growth pattern is 
transferable from one strain to another through capsule switch mutations. It further 
correlates with carriage prevalence, so that the serotypes with a more pronounced 
lag phase due to the burden of capsule production are less common in carriage and 
require more nutrient-rich growth media [125]. It has been proposed that high 
serotype prevalence in carriage is associated with metabolically less costly capsules 
that contain few carbons per repeat unit. These serotypes include 3, 6A, 6B, 14, 19F 
and 19A. As these serotypes are able to be more heavily capsulated without being 
metabolically burdensome for the bacterium, they are well protected from the 
immune system also when causing disease [329]. 
 
Given that the capsule is an important virulence factor, non-encapsulated isolates are 
only rarely encountered in clinical specimens [160, 278]. Studies of non-typeable 
isolates have revealed that several of the examined invasive isolates actually carried 
cps genes, although capsular detection by phenotypic means had been unsuccessful. 
It is possible that capsule production was downregulated in vitro [242, 278]. Non-
encapsulated pneumococci can also be grouped into clades, some of which are as 
successful at colonising mice as capsulated isolates [242]. Many of the restudied 
non-typeable carriage and non-invasive isolates did not carry any cps genes, or only 
carried disrupted genes that would not allow for capsular production [197, 278]. 
2.4.2 Serotype nomenclature 
In 1974, the Danish serotyping nomenclature was adopted internationally [122, 131]. 
Serotypes are known either solely by a number, e.g. serotype 14, or if serologically 
similar serotypes are known, these are gathered together into serogroups named by 
numbers, e.g. serogroup 7. For each serotype within a serogroup, a letter suffix is added, 
e.g. serotypes 7F, 7A, 7B, and 7C. In the majority of the serogroups, the first serotype to 
be described was assigned the letter F and any subsequent serotypes were named 
alphabetically starting with A [131]. The serotype nomenclature is based on the 
immunological properties of the capsule. However, the genetic study of cps revealed 
that sequence similarity is not necessarily greater within a serogroup than outside it. For 
example, serotypes 7B and 7C share a greater sequence similarity with serotype 40 than 
with serotypes 7F and 7A within the same serogroup [23]. 
 
2.5 Antimicrobial resistance 
The advent of the era of antibiotics reduced the mortality of serious pneumococcal 
infections and penicillin continues to be the primary antimicrobial drug for treating 
pneumococcal infections. [111]. For a long time, the pneumococcus was considered 
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to be universally susceptible to penicillin [117], although already in 1943, 
researchers had demonstrated that resistance to penicillin could be induced in the 
laboratory. Some 25 years after penicillin had become available and used in therapy, 
the first clinical pneumococcal strain that was non-susceptible to the drug was 
described in 1967 in Australia and soon after elsewhere [5, 60, 183]. Initially, the 
elevated minimum inhibitory concentrations (MICs) of the non-susceptible isolates 
were fairly low at 0.6 mg/L. The issue did not receive much attention until a decade 
later, when outbreaks involving invasive cases caused by pneumococci with higher 
level MICs (2-8 mg/L) were described in South Africa. The epidemic strain also 
exhibited resistance to chloramphenicol [5]. Following this observation, resistance 
to several other classes of antimicrobials such as macrolides, clindamycin, and 
tetracycline was described [5]. Since the 1980s and 1990s, non-susceptible or 
resistant pneumococci have been increasingly encountered in both invasive and non-
invasive samples all over the world [117]. Non-susceptibility to antimicrobials is 
most frequently observed in pneumococcal clones common among children and 
in carriage [137, 190, 291]. The reason is that carriage in children tends to be longer 
than in adults and their antimicrobial consumption can be frequent [291]. 
 
The clinical importance of pneumococcal non-susceptibility is a topic that is still 
much debated, but there seems to be agreement that at least resistance with high 
MIC is likely to have clinical significance [190]. Critics say factors independent of 
antimicrobial susceptibility may cloud the issue. Clinical failures may reflect 
circumstances other than the antimicrobial susceptibility of the pneumococcus. 
These include underlying disease, comorbidities, or old age of the patient, while 
other factors may be properties of the infecting strain, such as the serotype [190]. 
Some studies suggest penicillin-susceptibility has no major impact on the fatality 
rate of invasive pneumococcal disease episodes, but it is also important to note that 
certain serotypes with high invasive disease potential, such as serotype 1 and 7F, are 
only rarely observed to be non-susceptible to penicillin [285]. In a setting with low 
prevalence of resistance, antimicrobial drugs lower the risk of pneumococcal 
carriage [245]. However, a Canadian cohort study concluded that to predict the 
appropriate antimicrobial therapy for invasive pneumococcal disease, the physician 
should be aware of any antimicrobial use in the previous three months, as this is the 
most important risk factor for acquisition of a resistant strain [317]. Selection 
pressure brought on by antimicrobials is a risk factor for the acquisition of a non-
susceptible stain [6, 190]. 
 
Hand in hand with the clinical implications of resistance goes the interpretation of 
the susceptibility test results in the clinical and reference laboratories. The Clinical 
and Laboratory Standards Institute (CLSI), USA, issues susceptibility breakpoints 
for various pathogens and classes of antimicrobial agents. The breakpoints for 
bacteria issued by the European Committee on Antimicrobial Susceptibility Testing 
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(EUCAST) have been available since 2010, and differ in some parts from the CLSI 
breakpoints [93, 194]. Microbes are categorised by the use of breakpoints into 
susceptible (S), intermediate (I), and resistant (R) isolates. The intermediately and 
resistant isolates are collectively referred to as non-susceptible. In 2008, the CLSI 
breakpoints for pneumococcal penicillin-susceptibility were revised, taking into 
consideration clinical, pharmacokinetic, and microbiological aspects. Previously, 
one set of breakpoints had covered all types of cases, while the new breakpoints 
differentiate between meningitis and other cases [330]. By applying the new 
breakpoints, a larger proportion of the non-meningitis isolates are shifted to the 
penicillin-susceptible category, while a larger proportion of the meningitis isolates 
are moved to the resistant category [48].  
2.5.1 Modes of antimicrobial action and resistance mechanisms 
Just as the mode of antimicrobial action varies, the pneumococcal resistance 
mechanism also varies depending on the antimicrobial agent. 
 
Penicillin, cephalosporins, and other β-lactam antibiotics disrupt the integrity of 
the bacterial cell by interfering with a group of enzymes known as penicillin-binding 
proteins (PBPs) involved in the cell wall synthesis, eventually leading to bacterial 
lysis [344]. Cephalosporins have been improved upon in stages, so that each new 
generation of drugs has broader spectrum of antimicrobial activity than the previous 
one. Resistance to β-lactams in pneumococci is conferred by PBPs with lower 
affinity for penicillin. These PBPs develop through mosaic changes in the PBP-
encoding genes. While penicillin mainly reacts with PBP2b, the most important 
target for cephalosporins is PBP2x [95]. The changes affecting these proteins are 
acquired through homologous recombination of genes from other streptococci, 
whether other pneumococcal strains or other related species [60]. Four of the six 
pneumococcal PBPs are strongly implicated in resistance. Certain amino acid 
changes in PBP2b and PBP2x render the bacterium resistant, and additional changes 
in PBP1a are essential for high resistance [112, 289, 344]. Changes in PBP2a may 
also increase resistance further [60], and some of the other PBPs may occasionally 
be involved in resistance [117]. High cephalosporin-resistance, especially, cannot be 
explained solely by alterations in the PBPs [95]. It appears that mosaic changes in 
murMN operon, which encodes enzymes for branching peptidoglycan muropeptides, 
is vital for β-lactam resistance and that other mutations may also play important 
parts [60, 95, 96]. Pneumococcal penicillin-resistance is a complicated multifactorial 
process, and the variation of mosaic pbp alleles among resistant isolates is very high 
[117]. 
 
Macrolides were first discovered in the 1950s. Globally, pneumococcal macrolide-
resistance appeared in tandem with penicillin-resistance. Erythromycin and other 
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macrolides impede bacterial growth by binding to the 23S ribosomal RNA and 
inhibiting protein synthesis. Pneumococcal macrolide-resistance is usually mediated 
by either target site modification or active drug efflux, or both [60]. Target site 
modification is most commonly carried out by post-transcriptional methylation of 
the adenine in position 2058 of the pneumococcal 50S ribosomal subunit, which 
reduces attachment of the drug to its target site [84]. Methylation is performed by an 
enzyme usually encoded by the gene erm(B) or in some cases by erm(A) [60]. 
Expression of the transposon carried erm(B) results in resistance also against 
lincosamides, ketolides, and streptogramin B that all share a similar molecular target. 
This phenotype is named the “MLKSB phenotype” after the collective abbreviation 
of the antimicrobial agents in question [84, 318]. Active efflux of the drug from the 
bacterial cell is mediated by pumps encoded by the genes mef(A) or mef(E). This 
results in the so called “M phenotype” which provides resistance only against 
macrolides and displaying lower MICs than the MLKSB phenotype [84]. Dual 
phenotype isolates, i.e. isolates that carry both the erm and mef resistance 
determinants, exhibit a very high level of macrolide-resistance and are found 
especially among multidrug-resistant isolates [60]. In addition to target site 
modification and active efflux, pneumococci may carry ribosomal mutations that 
provide resistance by preventing the drug from binding to its target site. Such 
changes are similar to erm-mediated target site modification in that they often 
provide resistance to more than one group of antimicrobial agents [84]. 
 
Tetracycline antimicrobials are bacteriostatic drugs. Their main mode of action is 
blocking the bacterial protein synthesis by binding to the 70S ribosome. Recent 
archaeological finds suggests that tetracycline exposure may have been prolonged 
among the members of a Nubian tribe during Late Antiquity more than 1,600 years 
ago, but in the modern era, tetracycline was first taken into clinical use in the late 
1940s. For pneumococcal infections it is generally prescribed if other antimicrobials, 
such as penicillin, are contraindicated [231]. Tetracycline resistance is common 
among the bacteria found in the oral cavity, and can spread between oral and non-oral 
bacteria [226]. Pneumococcal tetracycline resistance is mediated by ribosome 
protection proteins encoded by tetM or occasionally by tetO [253, 318]. The tetM 
resistance gene may be located on the same transposon as erm(B), in which case the 
acquisition of macrolide and tetracycline resistance often occurs simultaneously [318]. 
 
Fluoroquinolones were originally formulated to treat Gram-negative bacterial infections.  
Their development against Gram-positive bacteria was prompted by the growing 
resistance of pneumococci against β-lactam antibiotics. Fluoroquinolones, such as 
levofloxacin, disrupt cell division by attaching to gyrase and topoisomerase enzymes 
that are essential for the supercoiling of DNA and for chromosome segregation 
[190]. Fluoroquinolone resistance is mediated by single-nucleotide polymorphisms, 
mutations in the genes encoding these enzymes leading to alterations in the 
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fluoroquinolone binding sites [67, 190]. In contrast to resistance against β-lactams, 
fluoroquinolone resistance is often the result of gradual accumulation of sporadic 
mutations in the quinolone resistance determinant region [60].  
2.5.2 Selection pressure and fitness cost of resistance 
Resistance to antimicrobial agents carries a fitness cost to the bacterium, and is more 
common in carriage isolates especially from children than in invasive isolates [291]. 
To offset the fitness cost of resistance, pneumococci may employ a number of 
strategies [60]. In one strategy, compensatory mutations, i.e. additional mutations in 
genes not directly involved in resistance, allow the maintenance of the resistance 
mechanism also in environments void of antimicrobial selection pressure by fully 
compensating for their fitness cost. Heteroresistance, on the other hand, is the 
presence of bacterial subpopulations that are capable of growth in higher 
antimicrobial concentrations than the bacterial population as a whole. It has been 
suggested that heteroresistance may allow pneumococci to test out resistance 
without the full fitness cost of a resistance mechanism [60, 219]. 
 
The development of resistance has been linked to antimicrobial drug consumption 
[254]. Subinhibitory concentrations of antimicrobials, which may occur in the body 
during or following treatment, induce an increase in pneumococcal mutation 
frequency, the so called hypermutation phenotype, which may give rise to resistance 
[60]. In studies conducted in Finland, high macrolide, trimethoprim-sulfametoxazole, 
and azithromycin consumption has been shown to increase pneumococcal resistance 
against these antimicrobials. The studies also linked β-lactam and cephalosporin 
consumption to low-level penicillin-non-susceptibility [25, 254]. A large European 
study also demonstrated this correlation both for the consumption levels of 
individual antimicrobial classes and for total antimicrobial consumption [268]. 
 
Non-invasive isolates usually display non-susceptibility to more antimicrobial 
agents than invasive isolates [137], possibly because the non-invasive isolates are 
exposed more often and to a greater number of antimicrobial agents than invasive 
isolates. However, as the same isolates may be involved in both invasive and non-
invasive disease, it has been suggested that optimal surveillance of antimicrobial 
resistance should take into account also a subset of non-invasive isolates and the 
drugs used for treatment of infections [175]. 
 
2.6 Resistance and clonality 
Pneumococcal resistance is clonal when certain genetic lineages or serotypes 
account for a large proportion of the non-susceptible isolates. Pneumococcal non-
susceptibility and resistance to penicillin and macrolides is mainly clonal, while the 
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clonality of resistance to fluoroquinolones is controversial, but unlikely to be clonal 
[60, 190]. In response to the observation of clonal antimicrobial resistance, the 
Pneumococcal Molecular Epidemiology Network (PMEN) was founded in 1997. 
The aim of the network was to standardise clone nomenclature and to curate a 
collection of well-characterised and globally disseminated clones [204, 261, 261]. 
To date, the collection includes forty-three clones with a wide geographic spread. 
The clones have been characterised by serotyping, antimicrobial susceptibility 
testing, multi locus sequence typing (MLST), and sometimes additional methods, 
such as pbp gene pattern analysis. Upon acceptance into the collection, PMEN 
assigns numbers to the clones and names them after their original country of 
isolation. In recent publications, the clones are sometimes referred to as PMEN and 
their clone number, e.g. PMEN1, rather than Spain23F-1 or Spain23FST81. In this text, 
the clones will be referred to by a combination of the two, i.e. PMEN1 Spain23FST81. 
This includes the PMEN clone number (PMEN1), original country of isolation 
(Spain), serotype (23F), and sequence type (ST81) as defined by MLST. More 
recently, the PMEN collection was expanded to include pneumococcal clones that 
are susceptible to antimicrobial agents, but clinically important and globally 
disseminated [261]. 
 
While all the PMEN clones have spread to at least two continents, their importance 
may vary between countries. By the late 1990s, 40% of the penicillin-non-
susceptible isolates studied in the USA were related to PMEN1 Spain23FST81 [60, 
61], while PMEN2 Spain6BST90 was responsible for the increase in penicillin-non-
susceptibility in Iceland in the early 1990s [172], and nearly half of the penicillin-
non-susceptible isolates in Poland in 2003-2005 and in Sweden in 2003 were related 
to PMEN3 Spain9VST156 [273, 284]. 
 
Serotype variants of the PMEN clones have been widely described. PMEN1 
Spain23FST81 has been found to express at least eight different capsules in addition 
to the original serotype 23F [67, 139, 227]. PMEN3 Spain9VST156, originally 
described as serotype 9V, was later widely found also displaying serotypes 14, 19F, 
19A, 11A, or 15C [57, 227]. The genetic lineage around the PMEN1 Spain23FST81 
clone looks fairly conserved when compared to other genetic pneumococcal lineages 
(Figure 4), displaying characteristics more often associated with young clones [293]. 
However, there are significant differences between isolates within the clone and 
even with the same serotype, regarding systemic virulence and moribundity in test 
animals [139, 147]. The ancestral strain of PMEN1 Spain23FST81 is likely to be one 
of the first penicillin-non-susceptible pneumococci isolated in 1967 in Australia 
[337], but mutations providing resistance to non-β-lactam antimicrobials have been 
acquired multiple times within the lineage either through horizontal gene transfer or 
spontaneous mutations [67]. The DNA of PMEN1 Spain23FST81 is also highly 
dispersed within the pneumococcal population and the clone has acted as a donor 
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especially for antimicrobial resistance determinants. For example, the PMEN1 and 
PMEN3 reference strains share identical pbp2x, pbp1a and pbp2b alleles that 
provide penicillin-resistance [337]. Genotypic variants differing from the PMEN 
clones in one or a few analysed genomic loci are also common. This illustrates the 
diversification of successful clones and the plasticity of the genome, although the 
number of variants and subgroup founders described vary markedly between genetic 
lineages (Figure 4) [227]. 
 
Non-encapsulated pneumococci are often non-susceptible to penicillin and can play 
a role in the development of resistance of capsulated isolates and clones. The rate of 
transformation of non-encapsulated isolates is higher compared to capsulated 
isolates, and by harbouring resistance genes, they are able to act as a vector for 
resistance [197]. The development from low to higher penicillin MIC by the transfer 
of resistance genes from non-encapsulated isolates has been demonstrated in the 
PMEN21 Portugal19FST177 clone in Switzerland [128]. 
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2.7 Studying the pneumococcal population by serotyping  
Before the era of antimicrobial resistance and serotype-specific vaccines, serotyping 
was not considered to be of high importance, as all serotypes were susceptible to the 
available antimicrobial agents [188]. As antimicrobial resistance developed and 
displayed serotype dependent associations, there was an increasing interest in 
characterising pneumococci further. All current vaccines offer protection against 
disease caused by a selection of serotypes, making serotype-based surveillance 
essential today. Serotyping also provides information about strain relatedness in 
outbreak situations and the serotype can be viewed as a clonal marker [124, 136]. 
Serotyping traditionally refer to grouping pneumococci by the immunological 
properties of their capsule, but lately, serotype deduction based on the genotype of 
the isolate has become widely used. 
2.7.1 Phenotypic serotyping methods 
Quellung, or the capsular reaction test, is the classic reference test for serotyping 
pneumococci. It is still performed largely in the same way as it was first described in 
1902, by mixing together broth culture of the strain to be studied and rabbit antisera 
on a microscope slide. The resulting reaction is observed in a phase contrast 
microscope. A positive reaction is marked by swelling of the capsule and frequently 
also agglutination of the bacterial cells (Figure 1) [12, 131]. Quellung is still much 
in use, but it requires a large panel of antisera, plenty of experience, and the 
individual handling of isolates. 
 
Other phenotypic serotyping techniques include latex or co-agglutination [224], 
counterimmunoelectrophoresis (CIEP) [133], dot blot [102], and Fourier-transform 
infrared spectroscopy with chemometrics [319]. Highly multiplexed flow cytometry-
based techniques using monoclonal and polyclonal antibodies have also been 
developed [182, 341, 342]. While the newer phenotypic methods all have their 
distinct benefits and often surpass Quellung in terms of rapidity and cost, some of 
the methods require sophisticated and expensive instruments. On the other side of 
the spectrum, the agglutination methods often rely on an array of self-prepared 
reagents [224], while in CIEP, the neutral serogroups 7, 14, 33, and 37 fail to 
produce precipitation lines [133]. 
2.7.2 Deducing the serotype by detecting the cps 
In recent years, several DNA-based techniques have been developed to facilitate 
serotype deduction from the genetic properties of the isolate. The PCR-based 
techniques are multiplexed amplification schemes targeting the genes that encode 
the enzymes required for the production of each serotype. The amplification and 
identification of the products is performed by multiplex PCR (mPCR) and gel 
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electrophoresis [240], by real-time mPCR [257], by reverse line-blot hybridization 
[167], or by mPCR with labelled oligonucleotide primers through fluorescent 
fragment size analysis [280] and capillary electrophoresis [177]. Because of 
sequence similarity between serotypes, certain serotypes or serogroups are co-
detected in PCR. In these cases, the results should be verified and subtyped by 
Quellung or other phenotypic serotyping methods. 
 
Serotyping based on sequencing, sometimes called molecular capsular typing, 
sequetyping, or capsular sequence typing, rely on partially sequencing the integral 
membrane regulatory protein gene wzg and the capsule biosynthesis protein-tyrosine 
phosphatase gene wzh, or partially or completely sequencing only the latter. In most 
serotypes, these two genes were previously denominated cpsA and cpsB, 
respectively. The obtained sequence is used to interrogate either a public genetic 
sequence database, such as GenBank [302], or a database set up for the purpose of 
serotyping pneumococci. An identical sequence in the database or the closest match 
gives the serotype of the isolate [87, 169, 180]. Phenotypic methods should be 
employed for the verification of all novel DNA sequences that do not yield an exact 
match. 
 
All nucleotide sequence-based serotyping schemes are by definition indirect, as they 
detect genes that encode for the proteins that synthesise the capsule, rather than the 
capsule itself. Researchers that discovered serotypeable isolates among strains that 
did not carry the expected cps genes caution against deducing the serotype of 
isolates without screening all cps genes [275]. An advantage of cps-based serotype 
deduction is that it enables typing of clinical samples rather than only cultured stains 
[124]. As nucleotide based methods have been increasingly employed, novel 
subtypes and features of the cps locus have been described and the diversity of the 
locus has been revealed. Upon closer study, it appears that the reference strain for 
serotype 22F published in 2006 contains the glycosyl- and acetyl-transferase genes 
wcwA and wcwC that are not present in all serological 22F strains [275]. Similarly, 
serogroups 6, 19, and 20 show sequence diversity. In the case of serogroup 20, this 
has led to the characterisation of a novel subtype, while serogroup 6 now comprises 
seven different proposed serotypes [42, 85, 164, 237]. Variations in the cps locus 
also include the proposed serotype 33E and genes present in a variety of non-
typeable presumably non-encapsulated isolates [275]. By verifying the species prior 
to serotyping or cps-sequencing, closely related species are excluded. In rare cases, 
other alpha-haemolytic streptococci may carry cps-like genes [45]. 
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2.8 Studying the pneumococcal population by genotyping 
The three first complete pneumococcal genome sequences were published in 2001 
and were obtained from virulent serotype 4 and 19F isolates and the commonly used 
avirulent non-encapsulated laboratory strain R6 [81, 142, 301]. Since then, several 
hundred pneumococcal whole-genome sequences have been completed or pursued 
to the draft level. These cover further non-encapsulated isolates and at least 30 
different serotypes including clinically important serotypes 3, 5, 6B, 9V, 14, 19A, 
19F, and 23F [65, 80, 139, 302]. 
 
The single pneumococcal genome consists of a circular chromosome, which is 2.0 to 
2.3 Mb in size (Figure 5). It has an average of just over 2,200 open reading frames 
and a GC content of 39.7%. On average, 74% of the pneumococcal genome is 
shared by all strains [80]. A core genome, consisting of just under 1,200 genes that 
are present in a single copy in all studied pneumococcal genomes, has been 
identified [65]. According to the so-called distributed-genome hypothesis, bacteria 
possess a supragenome, or pan-genome, which exceeds the genome size of any 
individual bacterium, but allow the species access to dispensable genes outside the 
core genome. These genes are utilised by the pneumococcus through genetic 
recombination as a means of diversity [140]. The pneumococcus is able to 
incorporate genes from other species as well, and Streptococcus mitis appears to be 
the main reservoir for pneumococcal genetic diversity [80]. 
 
While studies have shown that the capsule and serotype are the most important 
factors in pneumococcal virulence, the issue is far from simple. In some capsular 
switching experiments, the disease outcome has not been associated with the 
serotype, instead possibly indicating the genetic background of the stain as an 
important factor [205, 213, 285, 328, 329]. As with pneumococcal serotypes, certain 
genotypes are also more associated with invasive disease and others with carriage 
[71, 121]. To further complicate matters, there is also intraclonal variation between 
different strains of the same genotype [36]. In some studies, there is a strong 
association between serotype and genotype [39], but others found that for most 
serotypes, frequent recombination events disrupt the associations between genetic 
lineages and serotypes [80].  
 
Complete genome sequencing is the most thorough method of genetic analysis of a 
bacterial strain. However, several less costly and less labour-intensive standardised 
genotyping methods are generally used to provide a picture of the genetic 
background of the strain and its relationship to other known strains. These may be 
used for outbreak investigations, surveillance purposes, as well as for the 
determination of possible capsular switching events. Pulsed-field gel electrophoresis 
(PFGE) is a method in which the bacterial genome is digested with a rarely cutting 
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restriction enzyme and the resulting large DNA fragments are separated in an 
agarose gel with a pulsing field rather than a continuous field. The changing 
direction of the field facilitates separation of large DNA fragments and the resulting 
band profile is analysed with the help of computer software and compared to 
previously typed isolates [304]. While PFGE is a type of reproducible whole 
genome analysis, there is little consensus when it comes to profile naming and it is 
unclear whether the same sized bands in two strains actually represent the same 
piece of the genome [124]. 
 
 
 
Figure 5. A schematic drawing of the pneumococcal chromosome. The positions of the capsule 
polysaccharide synthesis locus (cps), multi locus sequence typing genes (aroE, gdh, gki, recP, spi, 
xpt, ddl), and penicillin-binding protein genes (pbp) are displayed. Adapted from Brueggemann et 
al, 2007 [37]. 
 
Multi locus variable number tandem repeat analysis (MLVA) makes use of repeat 
elements such as the so-called BOX elements, which are highly conserved repeat 
elements on the pneumococcal chromosome. Depending on the scheme, eight or 
sixteen repeat elements are amplified through simplex or multiplex PCR and sized to 
determine the number of repeats [86, 166]. 
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2.8.1 Multi locus sequence typing 
Multi locus sequence typing (MLST) relies on the amplification and sequencing of 
fragments of housekeeping genes located in the bacterial genome. The genes are 
chosen to represent variation that arises slowly over time and is selectively neutral, 
as the genes are vital for the survival of the bacteria. For the pneumococcal MLST 
scheme, internal fragments of about 450 bp each of seven genes were chosen [90]. 
The genes encode shikimate dehydrogenase (aroE), glucose-6-phosphate 
dehydrogenase (gdh), glucose kinase (gki), transketolase (recP), signal peptidase I 
(spi), xanthine phosphoribosyl transferase (xpt), and D-alanine-D-alanine ligase (ddl) 
(Figure 5). The obtained sequences of these loci are compared to the material 
deposited in the pneumococcal MLST database, which is located at Imperial College 
London and can be accessed over the internet [227]. Database interrogation yields a 
numeric allelic profile, e.g. 7-11-10-1-6-8-1, in which each number represents an 
allele of the seven housekeeping genes. This string is collectively called the 
sequence type (ST) of the strain and is identified by a unique number, e.g. ST156. 
The STs can further be assembled into genetic lineages or clonal complexes (CCs) 
through the based upon related sequences (eBURST) algorithm [75]. Each CC 
includes STs that are descended from a predicted primary founder ST, after which 
the CC is named, e.g. CC156. Submission of information about any genotyped 
isolate to the database is encouraged, and all novel sequences are submitted to the 
database curator for verification and inclusion in the sequence collection. In 
September 2013, the pneumococcal MLST database contained 20,867 isolates and 
9,061 unique STs [227]. 
 
MLST is currently the most widely used method for genotyping pneumococci. Its 
benefits include uniform and unambiguous nomenclature and interpretation, as well 
as the ease of comparing sequences and results between laboratories. The MLST 
database is accessible to anyone with access to the internet. The database is curated, 
which ensures the high quality of the deposited information [227]. Interpretation of 
MLST does not vary depending on the situation or source material, while different 
rules for PFGE interpretation may need to be implemented depending on the setting 
[304]. In an outbreak situation, PFGE may offer some advantages, as is a more 
discriminating method than MLST, which in turn, is either more or less 
discriminating than MLVA, depending on the scheme used [86, 311]. Genotyping 
by MLST corresponds well with whole-genome studies by microarrays and offers a 
good view of the genetic content of the strain, something that serotyping does 
relatively poorly [71]. MLST is also compatible with whole-genome sequencing, as 
the complete chromosomal sequence includes the housekeeping gene sequences 
used for MLST [124, 272]. To allow further discrimination between strains and 
bridge the gap between full genome sequencing and MLST, an expanded MLST 
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scheme has recently been developed. This is based on sequencing 96 variable loci 
flanked by conserved regions identified in the pneumococcal core genome [62]. 
 
2.9 Natural genetic transformation  
The ability to take up free DNA from the environment and through homologous 
recombination incorporating it into its own genome through transformation, i.e. 
natural competence, is an important characteristic of the pneumococcus [80]. In 
addition to the original observation of transformation of capsular synthesis genes, 
transformation of genes involved in other biochemical pathways, such as resistance 
to antimicrobial agents has been documented [65, 66, 337]. Transformation has led 
to marked diversity in pneumococcal populations and the abundance of mosaic 
genes in the pneumococcal genome [154]. The evolution of the pneumococcus is 
mainly brought about by the horizontal genetic exchange between other 
pneumococci and other species sharing the same ecological niche [80].  It has been 
estimated that a pneumococcal nucleotide site is approximately fifty times more 
likely to change through recombination than through mutation, and pneumococcal 
alleles are changed ten times more frequently by recombination than by mutation 
[100]. In a collection of PMEN1 Spain23FST81 isolates, nearly three quarters of the 
genome has been found to be affected by recombination events [66]. Further, this 
capacity for natural transformation has made the pneumococcus one of the most 
important model organisms for studying horizontal gene transfer through natural 
transformation in bacteria [129]. 
 
While natural transformation is a normal part of the physiology of the pneumococcal 
species, the bacteria are not constantly in a state of competence [129]. In laboratory 
cultures, competence is spontaneously achieved during the early logarithmic growth 
phase and lasts for up to an hour [24]. In pneumococcal biofilm communities, which 
are a form of sessile organisation found in nasopharyngeal carriage, the 
pneumococci show efficient transformation capacity compared to free planktonic 
growth. This may have important implications for the spread of resistance factors 
and capsular genes in the pneumococcal population, especially as co-colonisation 
with two different strains in the nasopharynx appears to increase the fitness and 
colonising capacity of the pneumococci [195, 196]. Attached pneumococci are also 
more resistant to antibiotic treatment than planktonic cells [195].  
 
The genes required for natural transformation are dispersed throughout the genome 
[129] and are co-regulated with lytic enzymes. The co-regulation has been explained 
by the fact that pneumococci engage in so-called fratricide, or sibling killing, in 
order to make naked DNA available. In fratricide, bacteria in the competent state 
produce and emit fratricins, muralytic enzymes that lyse bacterial cells. The predator 
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bacteria protect themselves against the bacteriolytic fratricins, while directing these 
means against non-competent target pneumococci [24]. Upon the death of the target 
bacteria, their DNA is released into the environment making it accessible to the 
predator bacteria [24, 54]. In addition to facilitation and acquisition of DNA uptake, 
the fratricins seem to provide a way of waging chemical warfare to eradicate 
competing bacteria and using the free DNA from lysed bacteria to promote genetic 
variation. The DNA also provides structural support in biofilm formation, which in 
turn helps protect the pneumococci from phagocytosis and complement mediated 
clearance [24, 79, 326].  
 
Capsular switching is one of the consequences of pneumococcal natural competence 
[14, 113]. Capsular switching refers to a pneumococcus of one genetic background 
taking the capsular type of another strain, by the transfer of cps genes and has been 
described in several genotypes and serotypes [154]. The other properties of the 
strain such as the antibiotic resistance profile and the genotype remain unaffected, 
unless the genes involved are included in the transferred DNA sequence [232]. 
Capsular switching may result in more effective evasion of the immune system and 
in increased virulence [66, 232]. When isolates of different serotypes co-exist for 
example in the nasopharynx, capsular switching and other forms of recombination 
may occur [196]. Capsular switching has been occurring regularly over the past 
seven decades, predating strong selection pressure asserted by the use of either 
antimicrobial agents or vaccines [336]. Capsular switching events may include 
recombination of cps flanking regions, in which case the PBP encoding genes pbp1A 
and pbp2X can be altered; however, the mean length of the recombination sequence 
is 2.3 kb [66, 336]. Antimicrobial induced pressure also appears to encourage 
pneumococcal transformation. The genes required for natural competence are 
activated by the presence of fluoroquinolones and aminoglycosidases and this may 
result in a resistant genotype [263].  
 
Several of the PMEN clones have serotype variants, where the genetic profile and 
ST is the same as the original strain, but the serotype is different, indicating that the 
clone has gone through capsular switching [67, 154, 227]. Within the PMEN3 
Spain9VST156 clone, switching from serotype 9V to serotype 14 has occurred at 
least twice and has been demonstrated through thorough experiments [57]. In the 
long term, the cps locus has undergone horizontal transformation between clones, 
but in the shorter term clonal expansion is likely to be more common than capsular 
switching, if the frequency of a serotype increases. This is illustrated by the 
association of the serotype and the genotype [38, 39, 90]. Reversely, in the MLST 
database, identical housekeeping gene alleles can be identified in isolates from 
differing CCs [75, 227], suggesting that the alleles may have relocated from one 
strain to another during natural transformation events. The ddl locus is usually 
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omitted from phylogenetic analysis because of its propensity to be involved in 
horizontal gene transfer events [89, 124, 227]. 
?
2.10 From whole-cell vaccines to polysaccharide and 
conjugate vaccines 
In the early 1900s, crude whole killed pneumococcal cells were used experimentally 
for immunisation and some efficacy against pneumonia could be seen [49]. When 
the capsular polysaccharide could be extracted in 1926, the ease of inoculation 
improved and led to successful vaccination studies in the 1930s and 1940s [193, 
325]. A hexavalent vaccine was licensed for human use following World War II, but 
in the advent of antimicrobial drugs the vaccines were neglected and eventually 
withdrawn [325]. 
 
The idea of vaccines as a means of preventing pneumococcal disease came back into 
favour in the 1960s after the appearance of antimicrobial resistance and the research 
into vaccine research was revived [193, 325]. In 1983, a 23-valent polysaccharide 
vaccine containing capsule polysaccharides of the most prevalent serotypes was 
introduced and it is still available today and useful for preventing disease among the 
elderly and in defined clinical risk groups [193, 215, 299]. 
 
Already in the late 1920s, researchers discovered that linking the pneumococcal 
capsular polysaccharides to foreign carrier proteins increases the obtained antibody 
response. Later on, this technology was used successfully to create a vaccine against 
another capsulated bacterial pathogen, H. influenzae type b, and in the past decades 
for the development of pneumococcal conjugate vaccines (PCVs) [193].The 
conjugate vaccines elicit a high immune response also in young children, the elderly, 
and the immunocompromised, unlike the polysaccharide vaccines [332]. The carrier 
protein in the PCV enables the activation of T-cells in eliciting an immune response 
and induces an immunological memory, something the polysaccharide vaccine fails 
to do [260]. 
 
The first pneumococcal conjugate vaccine was launched in the year 2000 in the 
United States and in 2001 in Europe. This heptavalent conjugate vaccine (PCV7) 
contains polysaccharides of serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F [327]. Since 
then, two other PCVs have been developed. In 2009, the 10-valent conjugate 
vaccine (PCV10), covering serotypes 1, 5, and 7F in addition to the PCV7 serotypes, 
was launched [241, 291]. A year later in 2010, an expanded version of PCV7 was 
introduced. This 13-valent conjugate vaccine (PCV13) contains antigens of 
serotypes 3, 6A, and 19A, in addition to the PCV10 serotypes [327]. The use of 
PCVs has successfully decreased the invasive disease incidence in areas with high 
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vaccine coverage. Among young children, the decrease has often been rapid and 
dramatic [9, 74, 82, 145, 150, 152, 212, 255, 271, 283, 331]. As of December 2012, 
86 (44%) of the WHO member states have introduced a PCV into their national 
vaccination programmes [47]. Low- and middle-income countries have not 
introduced PCVs in the same degree as high-income countries, although this is 
where most of the deaths from pneumococcal disease take place [158]. As a result, 
69% of the children born in the WHO member states are still ineligible for 
vaccination [47]. In Finland, the 10-valent conjugate vaccine has been part of the 
national vaccination programme since 1st September, 2010. It has since been offered 
free of charge to all infants born as of 1st June, 2010, at a 2+1 schedule, with 
immunisation at 3, 5, and 12 months of age [299]. Prior to universal childhood 
vaccination, a cluster-randomised PCV10 trial was conducted in Finland in the years 
2009 to 2010 [241]. Already in the first few years following implementation of 
PCV10 vaccination in the national vaccination programme, the number of invasive 
pneumococcal disease cases among young children has decreased [269]. 
 
2.11 Intervention and the pneumococcal population 
Both antimicrobial treatment and large-scale vaccination campaigns are 
interventions that affect the pneumococcal population as a whole. As resistance to 
commonly used antimicrobials such as penicillin and erythromycin is clonal, the 
consumption of antimicrobials favour the resistant clones, which may be allowed to 
acquire even further resistance determinants [60, 291, 312] Some studies have 
indicated that a decrease in the consumption of antimicrobials leads to a decline in 
resistance, but this is not always the case [6, 7]. Clonal spread of resistant lineages 
may reduce the impact on resistance levels of decreased consumption of antibiotics 
[7, 291]. Furthermore, large-scale vaccination and changes in the overall 
consumption of antimicrobials may have synergistic or conflicting effects on the 
resistance rates in a society [291]. 
 
The success of the PCVs, at least in the USA, is a combination of herd immunity 
and individual protection conferred by the vaccine and both carriage and invasive 
disease are affected by the vaccine [153, 327]. The use of a serotype-dependent 
vaccine will inevitably assert selection pressure on the pneumococcal population and 
it will lead to a decrease in vaccine serotype coverage, as the serotypes covered by 
the vaccine will be eliminated or decrease in the bacterial population. Another effect 
of the vaccines includes the so-called serotype replacement, in which non-vaccine 
serotypes gain from the decrease of vaccine serotypes by increasing in prevalence 
[212, 294, 327]. In the USA, the reduction in invasive disease was sustained in the 
seven years following PCV7 introduction [255], however, the positive effect of the 
vaccine may in time be partially eroded because of serotype replacement. As with 
Review of the literature 
 
 
 
THL — Research 119/2014 46 Clonality of Steptococcus pneumoniae in relation to antimicrobial resistance in Finland 
 
pneumococcal pathogenesis, serotype replacement in disease begins with 
colonisation. The incidence of non-vaccine serotypes have increased in carriage 
following vaccination [151, 327]. It has been demonstrated that PCV7 reduces the 
rates of colonisation with vaccines serotypes, but simultaneously increases the risk 
of non-vaccine serotype isolate acquisition [235] and the colonisation prevalence as 
a whole may not decrease following vaccination [148, 149]. There is indication of 
serotype replacement also in invasive disease [138, 146, 212, 228, 295]. For 
example, in France, the overall pneumococcal meningitis incidence in children 
returned to pre-vaccination levels after five years of PCV7 use, because of 
replacement primarily by serotypes 19A and 7F [181]. Capsular switching events 
allow the established clones circulating in the population to adapt to the post-vaccine 
environment by changing their serotype to a non-vaccine type, such as a switch from 
serotype 4 to serotype 19A in the PCV7 era [4, 37].  
 
Initially, antimicrobial resistance rates were expected to decrease following PCV use.  
Some studies report significant reductions in resistance, however, the results from 
different studies are contradictory and the long-term impact is still not clear [70, 206, 
228, 282]. Among carriage isolates, penicillin-resistance increased in one study due 
to non-PCV7 serotypes [120] and according to another study, invasive pneumococci 
are more likely to be non-susceptible to penicillin in the PCV7 era compared to the 
pre-PCV7 era [162]. The potential decrease in antimicrobial resistance has been 
further complicated by the emergence of multidrug-resistance as a feature of 
serotype replacement, mainly through the expansion of established multidrug-
resistant clones [21]. Serotype 19A is a frequently observed replacement serotype 
[212], and is often resistant to several antimicrobial agents. Among the PCVs, 
serotype 19A is covered only by PCV13 [70]. In the USA, the incidence of invasive 
19A disease increased following vaccination, while the resistance within this 
serotype increased markedly due to expansion of multidrug-resistant clones [21]. In 
Norway, where the antimicrobial selection pressure is low, the increase in invasive 
serotype 19A disease is caused mainly by penicillin-susceptible isolates [320].  
 
In addition to changes in the serotype distribution, the vaccine may also indirectly 
affect the epidemiology, because the serotypes vary in invasive potential and the 
diseases caused. While the incidence of parapneumonic empyema has been 
increasing worldwide even before PCV use, the emergence of non-vaccine serotypes 
has also had an impact on this complication [40, 174]. Following PVC-7 vaccination, 
the incidence of paediatric pneumococcal parapneumonic empyema increased in 
Utah, USA, probably due to replacement by non-vaccine serotypes such as serotype 
1 [41]. A similar situation among adults was described in Spain, where a virulent 
serotype 1 strain caused pneumonia with empyema after PCV7 implementation 
[110]. Non-PCV7 serotypes 1, 3, and, 19A are especially prone to causing empyema 
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[40]. Other non-vaccine serotypes, such as 22F and 33F, have been found to have a 
particular propensity to cause meningitis [315]. 
 
It has been suggested that ????pneumococcal vaccine strategy is at risk of Red Queen 
dynamics [153], a situation named after the character in Through the Looking-Glass 
by Lewis Carroll, who said “It takes all the running you can do, to keep in the same 
place” [44]. In evolutionary biology, Red Queen dynamics illustrate an arms race, in 
which a pathogen and its host organism co-evolve, leading to a situation in which 
their relative position to one another remains unchanged [191]. In the case of the 
pneumococcus and its human host, the vaccine development and improvement 
represents the evolution of the host, while serotype switching and serotype 
replacement represents the pneumococcal response. Both vaccine development and 
changes in serotype distribution respond and co-respond to the co-evolving party 
[153]. There are a few vaccine development strategies for overcoming the Red 
Queen dynamics. Firstly, a PCV covering all known serotypes would solve the 
stalemate. Because of cost and technical constraints regarding the limit of carrier 
protein and polysaccharides in a vaccine, this approach would more likely entail a 
set of PCVs, each covering a set of serotypes and together cumulatively covering all 
known serotypes. The second approach would be the development of a 
pneumococcal vaccine, which would be effective against all pneumococci and 
independent of serotype [153, 193, 216]. Several of the protein structures protruding 
from the pneumococcal surface have been proposed as multivalent vaccine 
candidates. Among these are the pneumococcal pili encoded by PI-1 and PI-2. 
Immunisation with PI-1 subunits has been shown to protect mice from lethal 
challenge from piliated pneumococci [16, 108, 223].  
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3 Aims 
The general aim of this study was to examine the clonality of the invasive 
pneumococcal population both on the serotype and the genotype level, focusing 
especially on pneumococcal clonality in relation to antimicrobial susceptibility. For 
a more comprehensive view of drug-resistant pneumococcal population, the 
clonality of a subset of multidrug-resistant non-invasive isolates was also examined. 
By combining clonal and virulence factor analysis, this study may be useful when 
future prevention strategies are considered and developed. 
 
 
The specific aims of this study were: 
 
• to study the clonality by serotyping and genotyping, as well as the 
antimicrobial susceptibility trends among the invasive pneumococcal 
population in Finland in the years 2002 to 2011 (Publications I and IV) 
 
• to study the clonality of a subset of multidrug-resistant non-invasive isolates 
(Publication II) 
 
• to set up and validate a serotyping scheme suitable for serotyping the 
invasive pneumococci in Finland (Publication III) 
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4 Materials and methods 
4.1 Bacterial isolates 
Table 2 presents the number of isolates included in the individual publications, the 
years of isolation, type of specimen and the collection or source of the isolates, as 
well as the number of isolates studied by the main methods. All isolates were stored 
in skim milk vials at below -65°C until needed and cultivated on 5% sheep blood 
agar at +37°C in an atmosphere enriched with 5% CO2. 
 
The publications I and IV include the pneumococcal isolates recovered from blood or 
CSF in Finland in 2002 to 2011 and collected in the Culture Collection of the NIDR 
housed at THL were studied. The isolates for which unpublished genotyping results are 
shown were intermediately penicillin-resistant pneumococci isolated in the year 2005. 
 
Based on previous results, positive control strains for species verification, the 
serotyping methods, and the PCR methods detecting macrolide resistance 
determinants and pilus-encoding genes were selected from the culture collections of 
THL, unless otherwise mentioned. For antimicrobial susceptibility testing, 
Streptococcus pneumoniae (ATCC® 49619™) was used for quality control. 
 
4.2 Species identification 
Verification of the bacterial species was performed primarily by colony morphology 
and by optochin sensitivity testing using optochin disks (Rosco Diagnostica, 
Taastrup, Denmark) [33]. When needed, the bile solubility test was performed by 
mixing bacterial culture in 10% sodium deoxycholate and noting lysis of the cells. If 
needed, the lytA gene was detected by PCR to confirm the species using a Taq 
polymerase (AmpliTaq Gold, Applied Biosystems, Foster City, CA, USA, or 
Maxima Hot Start, ThermoScientific, Waltham, MA, USA) and an annealing 
temperature of 60°C (Table 3). The Primer Basic Local Alignment Search Tool 
(Primer-BLAST) was used for primer design [303]. 
 
4.3 Isolation of DNA 
The genomic DNA of the bacterial strains was isolated either with the help of a 
column kit DNeasy Tissue kit (QIAGEN GmbH, Hilden, Germany) (Publication I) 
or by a heat lysis method in TE buffer containing Triton X-100, 1 % and Tween 20, 
0,5% (Publications I-IV) [214]. 
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Table 3. Oligonucleotide primers used in the study. 
Method 
Target 
gene(s)  
Primer sequence (5’-3’) 
Publicati
on 
Reference 
lytA TGGGGGCGGTTGGAATGCTG III This study Species 
verification lytA CCAGCCTGTTCCGTCCGCTG III This study 
aroE CGTTTAGCTGCAGTTGTT GC I-IV [88] 
aroE CCCACACTGGTGGCATTAAC I-IV [88] 
gdh ATGGACAAACCAGCNAGYTT I-IV [90] 
gdh GCTTGAGGTCCCATRCTNCC I-IV [90] 
gdh CTACAACTTCTTTCGCTCCT IV [27] 
gdh TGCCAAGTCCATTTGGCACC IV [27] 
gki GGCATTGGAATGGGATCACC I-IV [90] 
gki TCTCCCGCAGCTGACAC I-IV [90] 
recP GAATGTGTGATTCAATAATCACC I-IV [88] 
recP TTCGATAGCAGCATGGATGG I-IV [88] 
spi CGCTTAGAAAGGTAAGTTATG I-IV [259] 
spi AGGCTGAGATTGGTGATTCTC I-IV [259] 
MLST 
xpt CCACTACAACGGGAAATATTTGA I-IV [88] 
 xpt AGGATAGATCCTGAGTACATG I-IV [88] 
 ddl TTGCCATGGATAAAATCACGAC I-IV [250] 
 ddl CGCGCTTGTCAAAACTTTCC I-IV [27] 
 ddl AGCGTGTTCTGGAATCTGC IV [28] 
 ddl AGGTCAACCAAACGCTCG IV [28] 
erm(B) GAAAARGTACTCAACCAAATA I, II [103] 
erm(B) AGTAAYGGTACTTAAATTGTTTAC I, II [103] 
erm(A) CTTGTGGAAATGAGTCAACGG I, II [253] 
erm(A) TTGTTCATTGGATAATTTATC I, II [253] 
mef(A/E) GGCAAGCAGTATCATTAATCAC I, II [103] 
mef(A/E) GACTGCAAAGACTGACTATAG I, II [103] 
mef(A) TGGTTCGGTGCTTACTATTGT I [72] 
mef(A) CCCCTATCAACATTCCAGA I [72] 
mef(E) GGGAGATGAAAAGAAGGAGT I [72] 
macrolide 
resistance 
determinant 
detection 
mef(E) GCTATAAAATGGCACCGAAAG I [265] 
rlrA TCTGATAGATGAGACGCTGTTG I, II, IV [2] PI-1 
detection rlrA CTCCGCTTCTTTCTACTACAA I, II, IV [2] 
 rrgC GACTTCGTTTGAGATGACCCTTC I, II, IV [284] 
 rrgC GTCGTAACAGCATAGCCTGC I, II, IV [284] 
pitA-sipA CGTGGGTATCAGGTGTCCTATGATAA II, IV [16] PI-2 
detection pitA-sipA GCCTCGTCTTCTAATGACTGTTAC II, IV [16] 
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Method Target 
gene(s)  
Primer sequence (5’-3’) Public
ation 
Reference 
wzy CTTGTTTTCAAAYAAATGCAACTTT III This study 
wzy AGATTTGAAGAAATRACATAAGARAAA III This study 
19F-like 
19A wzy 
sequencing wzy GACGTATCTGCTTATATTTTTGGATATA III This study 
 wzy CCTCTATCCGTGTTCTTATCCGTGT III This study 
 wzy AAGAGTAGTAAAACGCTGGAATACCA III This study 
( Table 3. continues )
MLST, multi locus sequence typing; PI-1, pilus islet 1; PI-2, pilus islet 2 
 
4.4 Serotyping 
The serotyping of all studied pneumococci isolated before 2010 was performed 
using phenotypic antisera-based methods, i.e. latex agglutination, CIEP, the 
Quellung reaction test at a THL laboratory in Oulu (Publications I-IV). The 
serotyping of pneumococci isolated since 2010 was performed using an mPCR-
based scheme supplemented when needed by the Quellung reaction at a THL 
laboratory in Helsinki (Publication III-IV).  
 
The serotyping for the verification of the validation results (Publication III) was 
performed by Quellung at Statens Serum Institute (SSI), Denmark, according to 
instructions from the antisera manufacturer SSI Diagnostica, and by a monoclonal 
antibody based assay at the University of Alabama (UAB), Birmingham, USA [341]. 
 
The distinction of serotype 6C from serotype 6A has been possible since late 2009, 
but was performed retrospectively for the years 2007-2009; however, for the ten 
year study period these two serotypes were pooled together for analysis. The 
serotypes 10A and 10F/C were distinguished as of the year 2010, these serotypes 
were analysed at the serogroup level. 
4.4.1 Latex agglutination 
The neutral serogroups were identified by latex agglutination using antisera (SSI 
Diagnostica, Copenhagen, Denmark) and latex beads (Difco Laboratories Inc, 
Detroit, MI, USA). The latex antisera reagent was mixed together with the 
pneumococcus to be studied and observed for an agglutination reaction [179].  
4.4.2 Counterimmunoelectrophoresis  
Apart from the neutral serogroups, serotypes isolated prior to 2010 were identified 
primarily by CIEP using omni, pool, group or type, and factor sera (SSI 
Diagnostica). The pneumococci to be studied were harvested from overnight plate 
cultures, suspended in physiological NaCl solution, and heated in a water bath. After 
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cooling, droplets of suspension and antisera were placed in separate wells on a 
counterimmunoelectrophoresis gel and run in a counterimmunoelectrophoresis 
chamber [179]. Each gel was examined twice for precipitation lines between antisera 
and pneumococcal suspension. The 23-valent Pneumovax vaccine (Merck, Haarlem, 
Netherlands) was used as a positive control.  
4.4.3 The Quellung reaction  
The Quellung reaction was applied for serotyping, subtyping and confirmation, 
when needed. Fixed broth culture was with antisera (SSI Diagnostica) mixed on a 
microscope slide and the reaction observed in a phase contrast microscope. 
Physiological NaCl solution instead of antisera was used as a negative control. This 
method was used at the THL laboratories in Oulu (Publications I-IV) and in Helsinki 
(Publications III-IV), as well as at SSI for the verification of discrepant serotyping in 
the validation of mPCR-based serotyping (Publication III). 
4.4.4 Immunologic monoclonal antibody based serotyping assay  
Pneumococcal capsular polysaccharides (American Type Culture Collection, 
Manassas, VA, USA) were conjugated in separate reactions to distinct Luminex 
MicroPlex beads (Luminex Corporation, San Antonio, TX, USA). The bead mix 
was incubated with a pneumococcal lysate of the strain to be serotyped and pooled 
monoclonal antibodies (mAbs) on a filter bottom plate. After washing the beads, 
bound mAbs were detected with the help of phycoerythrin conjugated goat anti-
mouse immunoglobulin (BD Pharmingen, Franklin Lakes, NJ, USA) in a Bio-Plex 
200 analyser (Bio-Rad, Hercules, CA, USA) that detected the fluorescence signals. 
The obtained data was normalised to remove noise and determine the serotype of the 
isolate [341].  
4.4.5 Serotype deduction by multiplex PCR 
Setting up the serotyping scheme 
A serotyping scheme based on six consecutive mPCRs was compiled to cover 99% 
or the serotypes found among the Finnish invasive pneumococci by analysing the 
serotype distribution of 5,337 invasive isolates collected in 2002 to 2008 in Finland. 
Each of the six assembled sequential mPCRs detected six serotype or serogroup loci, 
as well as the capsular regulation gene wzg (cpsA) as an internal positive control. 
The most commonly occurring serotypes were included in the first two mPCRs. A 
separate mPCR (6C/6D mPCR) for detecting the presence of wzg (cpsA), the 
serogroup 6 specific wciP, and the 6C/6D capsule gene wciNβ was also set up 
according to a previously described mPCR [46]. The serotyping scheme was set up 
so that mPCRs would be performed until a serotype-specific amplicon was produced 
or if all six mPCRs had been performed without producing a serotype-specific 
amplicon the serotyping would be performed by Quellung, as described above.
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Table 4. Oligonucleotide primers for mPCR-based serotype deduction (III, IV). 
Serotype specificity Target gene mPCR Reference 
All* wzg (cpsA) All [240] 
1 wzy mPCR 4 [240] 
2 wzy mPCR 6 [68] 
3 galU mPCR 2 [240] 
4 wzy mPCR 2 [240] 
5 wzy mPCR 6 [240] 
6A/6B/6C/6D wciP mPCR 1, 6C/D mPCR [240] 
6C/6D wciNβ 6C/D mPCR [46] 
7A/7F wzy mPCR 2 [68] 
7B/7C/40 wcwL mPCR 5 [240] 
8 wzy mPCR 4 [68] 
9A/9V wzy mPCR 1 [68] 
9L/9N wzx mPCR 1 [76] 
10A wcrG mPCR 3 [240] 
10C/10F/33C wzx mPCR 3 [68] 
11A/11D wzy mPCR 3 [240] 
12A/12B/12F/44/46 wzx mPCR 3 [240] 
13 wzy mPCR 6 [68] 
14 wzy mPCR 1 [76] 
15A/15F wzy mPCR 4 [240] 
15B/15C wzy mPCR 2 [240] 
16F wzy mPCR 4 [68] 
17F wciP mPCR 6 [240] 
18A/18B/18C/18F wzy mPCR 2 [240] 
19A wzy mPCR 3 [258] 
19F wzy mPCR 2 [240] 
20 wciL mPCR 5 [240] 
22F/22A wcwV mPCR 1 [240] 
23A wzy mPCR 3 [68] 
23B wzx mPCR 6 [68] 
23F wzy mPCR 1 [240] 
25A/25F/38 wzy mPCR 5 [240] 
31 wzy mPCR 5 [240] 
33A/33F/37 wzy mPCR 5 [240] 
34 wzy mPCR 5 [240] 
35B wcrH mPCR 4 [240] 
35F/47F wzy mPCR 4 [240] 
39 wzy mPCR 6 [68] 
*The cpsA gene of some serotype 38 isolates is not amplified with these oligonucleotide primers. 
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Serotype deduction based on mPCR 
The amplification was performed in a 25 μl reaction volume with 35 thermal cycles 
and an annealing temperature of 54°C using a Taq polymerase (AmpliTaq Gold, 
Applied Biosystems, Foster City, CA, USA; or Maxima Hot Start, ThermoScientific, 
Waltham, MA, USA). All oligonucleotide primer names, targets, and sources are 
listed in Table 4. The genomic DNA of one positive control isolate for each 
amplified locus in each mPCR was used for the PCR-based serotyping scheme. The 
PCR products were visualized by gel electrophoresis using 2% NuSieve 3:1 agarose 
gels (Lonza, Rockland, ME, USA) in 1×TAE buffer run for 120 to 180 minutes. As 
a size marker the GeneRuler 50bp Marker (ThermoScientific) was used. Because of 
primer cross-reactivity and cps sequence similarity, the Quellung reaction described 
above was applied to distinguish co-detected serotypes, for subtyping when needed, 
and for serotyping if no serotype- or serogroup-specific product was obtained in any 
of the sequential mPCRs. During the protocol validation process, validation set 3 
was studied first by the 6C/6D mPCR, after which the Quellung reaction was 
applied for subtyping (Publication III). 
 
4.5 Antimicrobial susceptibility testing 
The applied breakpoints for the most important antimicrobial agents studied, the 
definition of multidrug-resistance, and the references for all breakpoints are listed in 
Table 5. When analysing the susceptibility for the whole ten year study period, the 
EUCAST 3.0 breakpoints were applied [93]. Antimicrobial susceptibility to 
penicillin, erythromycin, tetracycline, and clindamycin of all available isolates was 
performed by the plate dilution method at a THL laboratory in Turku (Publication I, 
II and IV) [252]. Susceptibility to levofloxacin was tested from August 2004 and 
susceptibility to ceftriaxone was tested from 2005 onwards. Additionally, the 
susceptibility to trimethoprim/sulfamethoxazole of the non-invasive isolates was 
tested (Publication II). The plates were cultivated in an atmosphere enriched with 
5% CO2. 
 
The susceptibility to penicillin, erythromycin, clindamycin, trimethoprim/ 
sulfamethoxazole, and doxycycline of the non-invasive isolates was initially 
determined by disk diffusion test and E-test at the clinical microbiology laboratory 
of the Hospital District of Helsinki and Uusimaa (Publication II). 
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Table 5. References for the breakpoints applied in antimicrobial susceptibility testing and 
multidrug-resistance definitions applied in the publications.  
Susceptibility breakpoints applied, minimum 
inhibitory concentration (MIC) Publication 
Penicillin Other antimicrobials 
Multidrug-resistance 
definition applied 
I* CLSI pre-2008 [56] 
? S ≤0.06 mg/L 
? R ≥2 mg/L 
CLSI pre-2008 [56], 
intermediate 
? ERY MIC ≥0.5 mg/L 
? TET MIC ≥4 mg/L 
Non-susceptibility to 
PEN, ERY, and TET 
II CLSI pre-2008 [56] 
? MIC ≥0.12 mg/L 
CLSI pre-2008 [56], 
intermediate 
? ERY MIC ≥0.5 mg/L 
? TET MIC ≥4 mg/L 
Non-susceptibility to 
PEN, ERY, TET, CLI, 
SXT, DOX 
IV CLSI pre-2008 [56] 
? S ≤0.06 mg/L 
? R ≥2 mg/L 
CLSI 2008 [55] 
? S ≤2 mg/L 
? R ≥8 mg/L 
EUCAST 3.0 [93] 
? S ≤0.06 mg/L 
? R ≥4 mg/L 
EUCAST 3.0 [93], 
intermediate 
? ERY MIC ≥0.5 mg/L 
? TET MIC ≥2 mg/L 
 
Non-susceptibility to 
PEN (MIC≥0.12 mg/L), 
ERY, and TET 
*Includes the isolates for which unpublished genotyping results are shown; S, susceptible; R, 
resistant; ERY, erythromycin; TET, tetracycline; CRO, ceftriaxone; CLI, clindamycin; SXT, 
trimethoprim/sulfamethoxazole; DOX, doxycycline 
 
4.6 Detection of macrolide resistance genes 
The macrolide resistance determinants of 223 randomly selected erythromycin-non-
susceptible isolates (MIC ≥0.5 mg/L) (Publication I) and of 12 multidrug-resistant 
non-invasive isolates (Publication II) were studied at a THL laboratory in Turku. 
Detection of the macrolide resistance determinants mef, erm(B), and erm(A) was 
performed by mPCR (Publications I and II). Separate PCR reactions were performed 
to differentiate between the efflux gene subclasses mef(A) and mef(E) in the mef 
positive isolates (Publication I). The oligonucleotide primers used are presented in 
Table 3, and the amplification was performed using the AmpliTaq polymerase 
(Applied Biosystems). 
 
4.7 Genotyping  
Selected isolates were genotyped by MLST (Table 2) [90]. The PCR reactions were 
performed using a Taq polymerase, either AmpliTaq Gold (Applied Biosystems, 
Foster City, CA, USA) or Maxima Hot Start (ThermoScientific, Waltham, MA, 
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USA). The oligonucleotide primers in Table 3 were used for both PCR and 
sequencing reactions. PCR product clean-up was performed by QiaQuick PCR 
Purification kit (QIAGEN GmbH, Hilden, Germany), the GeneClean Turbo kit (Q-
BioGene MB Biomedicals, OH, USA), the Edge Bio QuickStep 2 PCR Purification 
kit (EdgeBio Systems, Gaithersburg, MD, USA) or enzymatically using FastAP 
Thermosensitive Alkaline Phosphatase and Exonuclease I (ThermoScientific). 
Sequencing was performed using BigDye 1.3 chemistry (Applied Biosystems) either 
in ABI Prism Genetic Analyser (Applied Biosystems) or by full sequence service at 
the Institute for Molecular Medicine Finland (FIMM). The traces were analysed 
using either the Vector NTI Advance 10 or 11 software suite (Invitrogen 
Corporation, Carlsbad, CA, USA) or the Geneious Pro 5 or 6 software (Biomatters 
Ltd, Auckland, New Zealand) and compared with the material in the MLST database, 
according to which the STs were assigned [227]. Novel allele sequence traces and 
STs were submitted to the MLST database. Each ST was assigned to a CC by 
eBURST analysis using default stringent parameters [75]. The CCs were named 
after the predicted primary founder, i.e. the ST with the highest number of single 
locus variants (SLVs) at the time of writing each manuscript. For clarity and 
uniformity, all observed CCs were renamed after the predicted primary founder in 
September 2013. 
 
4.8 Detection of pilus-encoding genes 
The presence of pilus-1 encoding PI-1 genes (rlrA, rrgC) and pilus-2 encoding PI-2 
genes (pitA-sipA) were identified by PCR in selected isolates [2, 16, 284]. The 
isolates were selected as follows: in Publication I, the first penicillin resistant (MIC 
≥2 mg/L) isolate (n=27) of each serotype and ST as revealed by MLST, 2002-2006; 
in Publication II, the multidrug-resistant non-invasive pneumococci (n=12); in 
Publication IV, all penicillin-resistant (MIC ≥4 mg/L) isolates (n=12), 2007-2011. In 
Publication I, the isolates were studied only for the presence of PI-1. The annealing 
temperature was 59°C and the oligonucleotide primers are listed in Table 3. A Taq 
polymerase was used (AmpliTaq Gold, Applied Biosystems; or Maxima Hot Start, 
ThermoScientific). 
 
4.9 Sequencing of serotype 19F-like serotype 19A wzy 
The wzy gene of two serotype 19F-like serotype 19A isolates, which gave discrepant 
results by mPCR and Quellung based serotyping (Publication III), was sequenced using 
a primer walking strategy with the oligonucleotide primes in Table 3. The obtained 
sequences were edited and merged into contigs in Geneious Pro 5 software (Biomatters) 
and compared to the material deposited in the GenBank through the Basic Local 
Alignment Search Tool [303]. Finally, the sequences were submitted to GenBank. 
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4.10 Statistical methods 
Poisson regression was used for testing the statistical significance of antimicrobial 
resistance trends for the years 2002 to 2006 (Publication I). For testing the statistical 
significance of the log-linear antimicrobial resistance and serotype distribution 
trends, binomial regression with log-link was used in the SPSS Statistics 21 software 
(IBM, Armonk, NY, USA) for the years 2007 to 2011 (Publication IV). The latter 
method was used for analysis of overall serotype proportion trends and non-
susceptibility to erythromycin, tetracycline, and multidrug-resistance over the ten 
year period from 2002 to 2011. The penicillin-non-susceptibility and resistance 
according to EUCAST and pre-2008 CLSI breakpoints was analysed for the entire 
ten year period, as was non-susceptibility by serotype and age-group. The following 
age-groups were used: 0-2, 3-15, 16-64 and ≥65-year-olds. In the first five years of 
the study period, the two youngest age-groups were combined for statistical testing 
(Publication I). Penicillin- and erythromycin-non-susceptibility of the invasive 
isolates was studied by tertiary care district (Helsinki, Turku, Tampere, Kuopio, and 
Oulu) in five year periods (Publication I and IV). Risk ratio (RR) estimates per year 
and 95% confidence intervals (CI) were calculated along with P values. 
 
For detecting a possible association of PI-1 or PI-2 with serotype, serogroup, or ST, 
statistical analysis was performed by Fisher’s exact test using the Internet-based 
GraphPad Software (Publication II). P values <0.05 were considered statistically 
significant. 
?
4.11 Cost analysis 
Based on material usage per isolate at the time of the validation of the protocol, the 
cost of reagents and materials of serotyping was estimated for serotyping by 
Quellung and for the mPCR-based serotyping scheme including Quellung, when 
needed. The mean material cost of serotyping validation set 1 was considered for 
cost comparisons as this set best reflects the serotypes present in the Finnish 
invasive pneumococcal population (Publication III). 
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5 Results 
5.1 Serotypes among invasive pneumococci, 2002-2011 (I, IV) 
The proportions of the most important serotypes discovered are displayed in Figure 
6A and Figure 6B. The proportion of certain serotypes increased over the ten-year 
period. These were serotype 14, which increased from 13.5% (82/607) in 2002 to 
18.0% (143/794) in 2011 (RR, 1.03; 95%CI, 1.01-1.06; P=0.010); serotype 22F, 
from 3.5% to 8.8% (RR, 1.10; 95%CI 1.04-1.17; P=0.003); serotype 3 from 7.4% to 
9.7% (RR, 1.04; 95%CI, 1.00-1.08; P=0.032). The proportion of serotype 4 
decreased significantly from 13.6% in 2002 to 6.7% in 2011 (RR, 0.93; 95%CI, 
0.90-0.96; P<0.001). The proportion of serotype 9V also decreased from 8.9% to 
4.3% (RR, 0.90; 95%CI, 0.86-0.94, P<0.001). 
Taken separately, the two five-year study periods showed other significant serotype 
changes. Between 2002 and 2006, the proportion of serotype 6B increased from 
5.8% to 9.4% (RR, 1.10; 95%CI, 1.00-1.21, P=0.05), while between 2007 and 2011 
it decreased from 9.2% to 5.8% (RR, 0.91; 95%CI, 0.84-0.99; P=0.036). Reversely, 
the proportion of serotype 22F decreased in the initial five years from 3.5% to 2.7% 
(RR, 0.89; 95%CI, 0.84-0.94; P<0.001), while it increased in the latter five from 
4.3% to 8.8% (RR, 1.20; 95%CI, 1.06-1.37; P=0.005). The proportion of PCV10 
serotypes collectively remained stable in the first five years, but decreased between 
2007 and 2011 from 67.0% to 55.7% (RR, 0.97; 95%CI, 0.94-0.99; P=0.008). 
Serotype 6A decreased in the latter five years of the study (RR, 0.92; 95%CI, 0.86-
1.00; P=0.042), while the proportion of serotype 6C did not change in a statistically 
significant manner. 
There were significant changes in the serotype proportions in two age-groups from 
the year 2002 to 2011. Among the adults (16-64-year-olds), the proportion of 
serotype 14 increased (RR, 1.04, 95%CI, 1.01-1.07; P=0.004) reaching 20.0% in 
2011; and serotype 9V decreased (RR, 0.89; 95%CI, 0.85-0.94, P<0.001) covering 
5.2% of the isolates from this age-group in 2011. Among the elderly (≥65-year-olds), 
the proportion of serotype 22F increased (RR, 1.09, 95%CI, 1.03-1.14; P=0.002) 
reaching 9.4% in 2011, while serotype 9V decreased (RR, 0.91; 95%CI, 0.84-0.98, 
P=0.017). Among the elderly, serotype 9V covered 3.6% in the year 2011. 
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In the first five years for the study period, the hypothetical PCV7 serotype coverage 
was highest at 72% among the isolates derived from 0-2-year-olds and lowest at 
54% among those derived from 16-64-year-olds. The overall hypothetical serotype 
coverage for all age-groups and isolates was 58%. The hypothetical PCV10 
coverage was 81% of the isolates obtained from 0-2 year olds in 2007, and 72% in 
2011. The hypothetical PCV13 coverage in this age group was 84% in 2007, and 
88% in 2011. The hypothetical PCV13 coverage overall was 68% in 2007, and 73% 
in 2011.  
 
5.2 Antibiotic resistance among invasive pneumococci, 2002-
2011 (I, IV) 
5.2.1 Penicillin 
Over the ten year study period, the proportion of penicillin-non-susceptible (MIC 
≥0.12 mg/L) isolates among the invasive pneumococci increased from 8.0% (48/547) 
to 21.8% (173/794) (RR, 1.12; 95%CI, 1.08-1.15; P<0.001), range 8.0% to 23.3% 
(Figure 7).  
 
 
Figure 7. The proportion of penicillin-non-susceptible and -resistant isolates among invasive 
pneumococci isolated in 2002 to 2011.  
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The proportion of penicillin-resistant isolates according to the pre-2008 breakpoint 
issued by CLSI went from 0.8% (5/595) in 2002 to 3.5% (28/794) in 2011, range 
0.8% to 3.8%, but the increase was not statistically significant. The penicillin-
resistance proportion as defined by EUCAST also remained stable at 0.2% overall, 
range 0% to 0.6% (Figure 7). Only two isolates were found that were resistant to 
penicillin as defined by the 2008 CLSI breakpoint; these were isolated in 2010 and 
2011, respectively. 
 
When the five year study periods were examined separately, the proportion of 
penicillin-non-susceptible isolates (MIC ≥0.12 mg/L) doubled from 8.0% to 16.4% 
(RR, 1.15; 95%CI, 1.07-1.23; P<0.0001) and the proportion of penicillin-resistant 
isolates, as defined by the pre-2008 CLSI breakpoint, increased from 0.8% to 3.7% 
(RR, 1.18; 95%CI, 1.02-1.36; P=0.03). In the latter five years, the proportion of 
penicillin-non-susceptible isolates increased from 14.4% to 21.8% (RR, 1.11; 
95%CI, 1.05-1.17; P<0.001, but the penicillin-resistance did not change 
significantly. 
 
The proportion of penicillin-non-susceptible isolates was high within some 
serotypes (Figure 8), and in four serotypes it increased significantly over the ten-
year period. The proportion of penicillin-non-susceptible isolates among serotype 14 
increased from 25.0% in 2002 to 70.6% in 2011 (RR, 1.11; 95%CI, 1.08-1.15; 
P<0.001); among serotype 19A from 12.5% to 37.5% (RR, 1.13; 95%CI, 1.02-1.26; 
P=0.024); among serotype 4 from 1.2% to 26.4% (RR, 1.41; 95%CI, 1.28-1.54; 
P<0.001); among serotypes 6A and 6C combined from none to 11.4% (RR, 1.93; 
95%CI, 1.42-2.61; P<0.001). 
 
Over the ten year period, the proportion of penicillin-non-susceptible isolates 
increased in all age-groups. Among the 0-2-year-olds it increased from 15.7% 
(11/70) in 2002 to 29.7% (19/64) in 2011 (RR, 1.15; 95%CI, 1.08-1.21; P<0.001), 
among the 3-15-year-olds from 6.3% (2/32) to 31.0% (9/29) (RR, 1.18; 95%CI, 
1.10-1.26; P<0.001), among the 16-64-year-olds from 8.7% (28/324) to 20.8% 
(84/403) (RR, 1.12; 95%CI, 1.08-1.16; P<0.001), and among the ≥65-year-olds 
from 5.7% (10/179) to 20.4% (61/299) (RR, 1.07; 95%CI, 1.01-1.13; P=0.034).  
 
When studied separately in five year periods, the proportion of penicillin-non-
susceptible isolates increased only among the 16-64 year-olds (RR, 1.22; P<0.001) 
and among the ≥65-year-olds (RR, 1.15; P=0.02) in 2002 to 2006. In 2007 to 2011, 
the increase in the proportion of penicillin-non-susceptible isolates was not 
significant in the youngest age-group, however, there was significant increase in all 
other age-groups: among the 3-15-year-olds (RR, 1.23; 95%CI, 1.13-1.34; P<0.001), 
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the 16-64-year-olds (RR 1.11; 95%CI, 1.05-1.19; P=0.001), among the ≥65-year-
olds (RR 1.09; 95%CI, 1.03-1.14; P=0.002). 
 
 
 
Figure 8. Penicillin non-susceptibility in selected serotypes among the invasive pneumococci 
isolated in 2011, top panel. Erythromycin non-susceptibility in selected serotypes among the 
invasive pneumococci isolated in 2011, bottom panel. 
 
The proportion of penicillin-non-susceptible isolates (MIC ≥0.12 mg/L) in the year 
2011 varied between 18.2% and 25.6% in the five tertiary care districts. In the first 
Results 
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five years of the study, the proportion of penicillin-non-susceptible isolates 
increased significantly in the tertiary care districts of Tampere, from 5% in 2002 to 
15% in 2006 (RR, 1.25; 1.07-1.45; P=0.004), and Kuopio, from 5%  to 20% (RR, 
1.30; 1.04-1.61, P=0.02). The latter five years, the increase was significant in the 
districts of Helsinki from 18% to 26% (RR, 1.10; 95% CI, 1.01-1.20; P=0.033), 
Kuopio from 8% to 23% (RR, 1.30; 95% CI, 1.27-1.33; P<0.001), and Turku from 
11% to 19% (RR, 1.10; 95% CI, 1.00-1.22; P=0.044).  
 
In the first five years of the study, the hypothetical PCV7 coverage was 87% of the 
penicillin-non-susceptible isolates; in the last five years, the hypothetical PCV10 
coverage was 90% of the penicillin-non-susceptible isolates. 
5.2.2 Other antimicrobial agents 
The proportion of erythromycin-non-susceptible isolates increased over the ten-year 
period from 16.3% to 26.4% (RR, 1.05; 95%CI, 1.02-1.07; P<0.001), and was 
24.3% overall, range 16.3% to 28.9% (Figure 9). In the first five years, the increase 
was significant from 16.3% to 28.4% (RR, 1.12; 95%CI, 1.06-1.18; P<0.001), 
however in the latter five years the proportion did not increase significantly and was 
26.6% overall, range 23.2% to 28.9%. 
 
 
Figure 9. The proportion of invasive isolates non-susceptible to erythromycin and tetracycline, 
respectively, and the proportion of multidrug-resistant (MDR) isolates non-susceptible to PEN, 
ERY, and TET among the invasive pneumococci in Finland in 2002 to 2011. 
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The proportion of erythromycin-non-susceptible isolates was consistently highest in 
the youngest age-group. In the year 2011, the proportion of non-susceptible isolates 
was 46.9% among isolates from 0-2-year-olds, 27.6% among isolates from 3-15-
year-olds, 25.6% among isolates from 16-64-year-olds, and 23.1% among isolates 
from ≥65-year-olds. The proportion of non-susceptible isolates increased among the 
isolates from all tested age-groups during the first five-year period, 2002 to 2006: 
among the 0-15-year-olds (RR, 1.12; P=0.01); among the 16-64-year-olds (RR, 1.11; 
P=0.003); and among the ≥65-year-olds (RR, 1.16; P<0.001). In the latter five years, 
there was a significant increase in non-susceptibility over the study period only 
among the 16-64-year-olds (RR, 1.06; P=0.049). 
 
In the year 2011, the proportion of erythromycin-non-susceptible isolates varied 
between 18.7% and 34.3% among the five tertiary care districts. In 2002 to 2006, a 
significant increase in the proportion of erythromycin-non-susceptible isolates was 
observed in the tertiary care district of Tampere from 7% to 29% (RR, 1.35; 95%CI 
1.22-1.51; P<0.001) and Oulu from 20% to 28% (RR, 1.12; 95% CI 1.00-1.25; 
P=0.04). In 2007 to 2011, the non-susceptibility increased significantly only in the 
district of Kuopio from 22% to 29% (RR, 1.07; 95% CI, 1.04-1.10; P<0.001). 
 
In the first five years of the study, the hypothetical PCV7 coverage of the 
erythromycin-non-susceptible isolates was 80%, and in the last five years, the 
hypothetical PCV10 coverage was 86% of the erythromycin-non-susceptible isolates. 
Serotype 14 especially, but also certain other serotypes, contained a high proportion 
of erythromycin-non-susceptible isolates in the year 2011 (Figure 8). 
 
The proportion of tetracycline-non-susceptible isolates decreased slightly over the 
ten years from 9.8% to 6.0% (RR, 0.94; 95%CI, 0.91-0.98; P=0.001) and was 8.9% 
overall, range 6.0% to 13.0% (Figure 9). When studied separately, there was no 
significant change during either of the two five year periods. 
 
Ceftriaxone susceptibility was studied from 2005 onwards and 3.7%, range by year, 
2.5% to 4.2%, of all tested isolates were non-susceptible to this antimicrobial agent. 
Twelve isolates or 0.2% had ceftriaxone MICs ≥2 mg/L. The non-susceptibility to 
levofloxacin was similarly rare at 0.2% overall, with 16 non-susceptible isolates 
discovered since testing started in August, 2004. 
 
The proportion of multidrug-resistant isolates, defined as non-susceptibility to 
penicillin, erythromycin, and tetracycline, was 4.2% overall, range 3.3% to 5.6%, 
and did not change significantly over the ten years or in the two five year periods 
(Figure 9). Of the erythromycin-non-susceptible isolates, 38% (2002-2006) and 55% 
(2007-2011), respectively, were also non-susceptible to penicillin (MIC ≥0.12 mg/L). 
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Overall, 74% (2002-2006) and 76% (2007-2011), respectively, of the penicillin-non-
susceptible isolates were also non-susceptible to erythromycin. 
 
5.3 Macrolide resistance determinants among the invasive 
pneumococci, 2002-2006 (I) 
The mef gene was the most common macrolide resistance determinant. It was 
carried by 56% of the 223 randomly selected erythromycin-non-susceptible isolates. 
Of the subtyped mef positive isolates, 72% carried mef(E) and 28% carried mef(A). 
All mef(A) positive isolates were serotype 14 and susceptible to penicillin, which 
suggests they may be clonally related. The erm(B) gene was present in 30% of the 
screened isolates. Double carriage of macrolide resistance determinants, mef(E) and 
erm(B), was displayed by only two of the studied isolates (0.9%). These isolates 
were both serotype 19F and part of CC320. The macrolide resistance mechanism 
remained unknown in 13% of the studied isolates. 
 
5.4 Genotype clonality of penicillin-resistant and -non-
susceptible invasive pneumococci, 2002-2011 (I, IV) 
Among the penicillin-resistant (MIC ≥2 mg/L) invasive isolates from 2002 to 2006, 
25 STs belonging to nine CCs and one singleton was discovered. The CCs and their 
STs were CC156 with ST156, ST2918, ST2306, ST3247, ST143, ST2916, ST671, 
ST90, ST3246, and ST138; CC320 with ST236, ST271, ST2694, ST2917, and 
ST3245; CC81 with ST81, ST961, and ST3250; CC15 with ST13; CC63 with 
ST2687; CC496 with ST496; CC205 with ST205; CC460 with ST461; and CC2599 
with ST3248. The singleton was ST3249. 
 
The penicillin-resistant (MIC ≥4 mg/L) isolates from 2007 to 2011 displayed eight 
STs belonging to two CCs, CC156 and CC320. These CCs were present also among 
the highly penicillin-resistant invasive isolates in the previous five-year period 
(Table 6). 
 
The penicillin-non-susceptible isolates (MIC 0.12-1.0 mg/L) from the year 2005 
displayed 34 different STs belonging to 14 CCs and one singleton (Table 7). 
 
Among all the invasive penicillin-non-susceptible isolates genotyped by MLST, 14 
novel STs were discovered. Among these, four novel ddl alleles, and one novel 
allele at the aroE, gki, recP, and xpt loci each were discovered. CC320 and lineage 
termed i within CC156, as defined by the eBURST algorithm are shown in Figure 
10 and Figure 11, respectively. 
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Figure 10. CC320 as defined by the eBURST algorithm [75]. The predicted CC founder ST320 is 
depicted in blue, subgroup founders in yellow. The magenta halos depict isolates found in the 
material in this study, all CC320 STs from both the invasive and the non-invasive isolates in 
Publications I, II, IV and Unpublished, Siira et al. are included. 
 
Figure 11. The genetic lineage i within CC156 as defined by the eBURST algorithm and the 96-
MLST scheme [75, 221]. The magenta halos depict isolates found in the material in this study, the 
CC156 STs from both the invasive and the non-invasive isolates in Publications I, II, IV and 
Unpublished, Siira et al. are included. The complete CC156 is depicted in Figure 4. 
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5.5 Pilus islets among the penicillin-resistant invasive 
pneumococci, 2002-2011 (I, IV) 
Pilus islet carriage was limited to STs of certain CCs. Among the penicillin-resistant 
pneumococci (MIC ≥2 mg/L) isolated from 2002 to 2006, PI-1 was carried by the 
isolates in CC156, CC320, CC205 and the singleton ST3249. CC81, CC460, 
CC2599, CC15, CC63 and CC496 were negative for PI-1. The isolates isolated 
before 2007 were not studied for the presence of PI-2. Of the penicillin-resistant 
(MIC ≥2 mg/L) isolates from the years 2002 to 2006, 79.5% carried PI-1 if 
extrapolated from the results of the studied ST representatives. In 2007 to 2011, all 
penicillin-resistant isolates (MIC ≥4 mg/L) carried PI-1, and in addition, the 
serogroup 19 CC320 isolates (75%) also carried PI-2 (Table 6). 
 
5.6 Characteristics of non-invasive multidrug-resistant 
pneumococci (II) 
Five serotypes were found among the 12 isolates: 19F (n=5), 19A (n=3), 6B (n=2), 
23F (n=1), and 14 (n=1). Six STs from three genetic CCs were represented: CC320 
with ST271 (n=4), ST1451 (n=3), ST283 (n=1); CC156 with ST90 (n=2), ST2918 
(n=1); and CC81 with ST81 (n=1). CC320 claimed all serogroup 19 isolates. CC320 
and the lineage termed i within CC156, as defined by the eBURST algorithm, are 
depicted in Figure 10 and Figure 11, respectively. Of the 12 isolates, 11 (92%) 
carried PI-1 and 8 (67%) carried PI-2. All CC320 isolates were positive for both 
pilus islets, while the CC156 isolates were positive only for PI-1. The CC81 isolate 
was negative for both pilus islets. PI-2 was associated with serogroup 19 and with 
CC320 (P=0.002). All CC320 isolates displayed the double macrolide resistance 
determinant phenotype, carrying both erm(B) and mef(A/E), while the CC156 and 
CC81 isolates carried only the erm(B) gene. 
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5.7 Validation of the mPCR based serotyping scheme (III) 
Overall, the three sets consisted of 42 different serotypes and three non-encapsulated 
pneumococci and one non-pneumococcal isolate (Figure 12). The initial results 
obtained at the two THL laboratories by mPCR-based serotyping supplemented with 
Quellung (Figure 13) in Helsinki and by traditional immunological methods in Oulu, 
were compatible for 95.3% (162/170) of the isolates overall. For the first validation 
set, the results from the THL laboratories in Helsinki and Oulu were congruent for 
97% (68/70) of the isolates; for the second set, for 96% (67/70) of the isolates; and 
for the third set, for 90% (27/30) of the isolates. For the serotypes where the 
protocols used differed in resolution power, results such as serotype 10F/C vs. 
serogroup 10 were not considered contradictory. 
 
 
 
 
 
 
 
Figure 12. Serotypes included in the three validation sets (serotype; number of isolates) sorted by 
serogroup. Serotypes are named to the level that is in use for the mPCR based serotyping scheme 
for invasive pneumococci in Finland. PNC, pneumococcus; NC, non-encapsulated. 
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External verification of discrepant serotyping results was performed at one or both 
of the reference laboratories at SSI and UAB. Following external verification, the 
results obtained by the mPCR-based serotyping scheme were compatible with the 
verified results for 98.6% (69/70) of the first validation set, 98.6% (69/70) for the 
second set, and 100% (30/30) for the third set. The combined compatibility between 
the results obtained by the mPCR based serotyping scheme and the external 
reference laboratory results was 98.8% (168/170). For isolate IH163205-2, serotype 
6D, the serotyping performed at UAB was considered decisive, as this was where 
serotype 6D was first described and studied in detail [34, 35]. The results for this 
isolate have been published separately [229]. For isolate IH163216-4, the result of 
non-pneumococcus from SSI was considered decisive, as species verification tests 
had been performed there. 
 
Together, the first two mPCRs were anticipated to give a result for over 80% of the 
invasive isolates when setting up the new serotyping scheme (Figure 13). This 
expectation proved accurate, as 86% of the invasive pneumococci isolated in the 
initial 18 months of application produced either a serotype or serogroup specific 
amplicon in one of the first two mPCRs. Routine application of the serotyping 
scheme was successful and interpretation of the electrophoresis gel amplicon 
patterns was straightforward. It also confirmed that the six main mPCRs combined 
produced a serotype- or serogroup-specific mPCR amplicon for 99.4% of the 
Finnish invasive isolates. 
 
For serotyping validation set 1, the approximate mean material cost by Quellung 
was 17 € per isolate, range 14-20 €. The approximate mean material cost for 
serotyping by the mPCR based serotyping scheme including Quellung when needed, 
as depicted in Figure 13, was 6 € per isolate, range 3-13 €. 
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Figure 13. Flowchart for multiplex PCR based serotype deduction supplemented with Quellung. 
The wzg amplicon is the positive internal control. *6C/D mPCR has not routinely been used since 
mid-2010; ** since late 2010 all mPCR 19F-positive isolates have been confirmed by Quellung 
subtyping.
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5.8 The genotypes and wzy sequences of two serotype 19F-
like 19A isolates 
Two isolates that produced the 19F specific amplicon in mPCR 2, but were serotype 
19A when examined by Quellung, were studied by MLST. These isolates had novel 
STs. Isolate IH163643-0 had ST8025 and had the allelic profile 1-5-41-5-9-1-18, 
while isolate IH166473-6 had ST8026 and had the allelic profile 13-8-4-5-9-1-18.  
 
The sequenced wzy genes were identical in both isolates and showed 93-92% 
identity with the serotype 19F wzy genes and 80% identity with the serotype 19A 
wzy genes from other isolates found in GenBank. The wzy gene sequences of isolates 
IH163643-0 and IH166473-6 were deposited in GenBank under the accession 
numbers JX112900 and JX112901, respectively.  
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6 Discussion 
6.1 Serotypes among the invasive pneumococci 
The proportions of individual serotypes may fluctuate over time in a pneumococcal 
population even prior to extensive use of vaccines or antimicrobials. The use of 
antimicrobials is likely to have affected the serotype distribution before systematic 
surveillance of resistance was implemented [99, 122]. In this study, the three most 
frequently identified serotypes in the years 2002 and 2007 were all included in 
PCV10. The serotypes were 4, 14, and 9V in 2002; and 14, 6B, and 4 in 2007.  In 
contrast, in 2011, the three most frequent serotypes were 14, 3, and 22F, and the 
proportion of all these serotypes increased over the study period. Serotype 14 
covered 17.5% of the isolates from the whole period, while it only covered 12.2% of 
invasive pneumococcal disease cases in 1995 to 2002 [163]. The increase of 
serotype 22F, especially, was quite dramatic in the last year of the study reaching 
8.8% in 2011. In 1995 to 2002 serotype 22F covered only 3.5% of the isolates [163]. 
Of the three most common serotypes isolated in 2011, only serotype 14 is a vaccine 
serotype, while serotypes 3 and 22F may turn out to be important in replacement 
following PCV10 vaccination. Serotype replacement by serotype 3 and 22F has been 
described elsewhere following PCV7 use [212, 249]. In this study, the proportions 
of the PCV10 serotypes 4 and 9V declined over the study period of ten years, 2002-
2011. In the latter half of the study period, the PCV10 serotypes combined also 
decreased, although they had remained stable in the previous five years. These 
changes may not be a direct consequence of vaccine use, but their timing is 
interesting in relation to the PCV10 implementation in Finland in September 2010, 
and they warrant careful monitoring in the coming years. It has been proposed that 
replacement serotypes will include serotypes which are metabolically less costly for 
the bacteria to produce and therefore may be more heavily capsulated [329]. These 
low carbon containing serotypes include serotype 3, while other potential 
replacement serotypes proposed by this theory are 19A and 6A. 
 
The hypothetical serotype coverage calculated based on the serotypes discovered in 
this material may not give the complete picture. For PCV13, the immunological 
response to serotype 3 has been low in some studies, for example [233]. This is an 
important consideration to bear in mind when comparing the serotype coverage 
provided by different PCVs, especially as the proportion of serotype 3 has been 
increasing in Finland, possibly partly in response to the use of PCV10. The 
distribution of invasive serotypes may also differ markedly for example from the 
distribution of serotypes in non-bacteraemic pneumococcal pneumonia. This was 
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illustrated by a recent Danish study, in which the PCV10 and PCV13 serotypes 
covered only a sixth and a third of non-invasive cases, respectively, while the 
proportions were much higher for the bacteraemic cases [22]. In a study from the 
UK, the loss of quality of life, clinical presentation, and mortality was calculated and 
found to differ markedly between serotypes, giving different vaccines different 
disease coverage profiles [315]. 
 
The proportions of serotype 14 and serotype 9V changed radically and 
simultaneously from one year to the next during the study. These changes took place 
from 2005 to 2006, when serotype 14 increased, while serotype 9V decreased. It is 
tempting to speculate that this may have been caused by the rise of a particularly 
successful serotype 14 clone at the expense of a declining serotype 9V clone. 
 
Interestingly, serotype 3, has in some studies been found to display low invasiveness 
[38], but was frequently encountered in invasive samples in Finland during the 
whole ten year period. Other studies have found that this serotype has a high 
invasive disease potential especially among adults and the elderly, and also high 
mortality [249, 285, 339]. On the other hand, serotype 1, which has high invasive 
disease potential [38], is very rare among the invasive isolates in Finland. This may 
perhaps be explained by the low number of strains of this serotype circulating in 
human society. Similarly low serotype 1 proportions have been described in the 
USA, Canada, and Australia, while in much of Europe, Asia, Latin America and 
Africa higher proportions of up to 30% are found [127]. 
 
6.2 Recently discovered and aberrant serotypes 
6.2.1 Serogroup 6 
In the years covered by this study, several novel serotypes have been discovered. 
This is most notable within serogroup 6, where the two previously known serotypes, 
6A and 6B, have been joined by serotypes 6C and 6D, and even more recently, by 
the proposed serotypes 6E, 6F, and 6G [34, 164, 237, 244]. Serotypes 6A and 6B, 
the two oldest members of this serogroup, were described in the late 1920s [130]. 
Genetically, they differ from each other only by a single nucleotide polymorphism at 
the 584 bp position in the wciP gene, which changes the amino acid residue at 
position 195 [200, 292]. This is the genetic basis for the different rhamnose ribitol 
linkages found in the serotype 6A and 6B capsular polysaccharides: a 1,3 linkage in 
serotype 6A and a 1,4 linkage in serotype 6B [200].  
 
Serotype 6A subtypes were suspected already in 2006, when “dodgy 6As” isolates 
were found. These bound only to certain types of monoclonal antibodies developed 
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against serotype 6A and displayed a weak reaction with the Pool B antiserum in the 
Quellung reaction [123, 182]. A year later, the genetic basis for serotype 6C was 
described. This serotype is similar to serotype 6A, but carries the wciNβ gene, a 
roughly 200 bp shorter version of the serotype 6A wciNα gene. The gene product is a 
α-1,3-galactosyltransferase involved in capsular production. Pneumococci with this 
serotype have been isolated from both invasive and non-invasive samples from 
around the world [243]. 
 
A few years after the discovery of serotype 6C, the same research group generated 
an analogous variant of serotype 6B, i.e. an isolate that harboured the serotype 6B 
wciP gene, but also carrying the wciNβ gene. This serotype was named 6D [35]. 
Isolates carrying this capsular type were later discovered among natural clinical 
isolates [34], and a study from South Korea has established that serotype 6D has 
been circulating there at least since 1996 [51]. In Finland, three serotype 6D isolates 
have been discovered among the invasive pneumococci since the initial publication 
of the serotype. The isolates are included in this study, and one of them has been 
described separately [229]. In addition to this, there are only a handful of reports of 
invasive serotype 6D isolates worldwide to date [51, 173, 199, 262, 346]. According 
to reports from several countries, it appears to be more commonly encountered 
among non-invasive isolates [151, 157, 165, 208, 236, 276]. 
 
In this study, the serotype 6A isolates from the years 2007 to 2011 were studied 
either by 6C/6D mPCR or the Quellung reaction to differentiate the serotype 6C 
isolates. This showed that serotype 6C had been present among the invasive isolates 
at least since the year 2007. As not all previous serotyping results have been 
confirmed using the larger selection of serogroup 6 specific antisera or the 6C/6D 
specific mPCR, it is likely that these newer serotypes may be present also among 
older isolates. Serotype 6C has been in existence at least since 1979 [243] and it 
appears that the serotype 6C cps has appeared through several independent capsular 
switching events within several different genetic lineages [187]. Because of its rarity 
among the invasive pneumococci isolated since 2010, there has at this time been no 
attempt to retrospectively distinguish serotype 6D from 6B in Finland. It is still 
unclear whether the other proposed serotypes of this serogroup, serotypes 6E, 6F 
and G, are more likely to be encountered in invasive or non-invasive sites and how 
common they are. 
 
This study and others show that among the serogroup 6 serotypes, penicillin-non-
susceptibility is most frequent in serotype 6B. Serotype 6A isolates display non-
susceptibility (MIC ≥0.12 mg/L) in some cases, though rarely full resistance [202, 
313]. Penicillin-non-susceptibility among serotype 6C is low, but has increased at 
least in the USA, exceeding 30% among invasive isolates in the year 2007 [46]. In 
Portugal, multidrug-resistance among serotype 6C has been on the increase [234]. In 
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the Finnish material, only one penicillin-non-susceptible serotype 6C isolate was 
discovered between 2007 and 2011, therefore one can conclude that the increase in 
non-susceptibility in serotype 6A and 6C combined is largely due to serotype 6A 
non-susceptibility. All three Finnish serotype 6D isolates in this study were 
susceptible to the tested antimicrobials, and many other studies similarly report 
penicillin-susceptible serotype 6D isolates [202, 313, 346]. However, in a large 
collection containing both invasive and non-invasive serotype 6D isolates from 
Israel, more than 90% displayed non-susceptibility to at least one antimicrobial 
agent and multidrug-resistance exceeded 70% [262]. This finding underlines the 
importance future monitoring, especially as non-invasive pneumococcal clones 
appear to have a tendency to develop resistance [137].  
 
From a PCV standpoint, the discovery of any new serogroup 6 serotypes is of 
interest. Serotype 6B is included in all three available PCVs, and additionally, 
serotype 6A is included in PCV13. The discovery of serotype 6C raised concerns of 
post-vaccination replacement. Indeed, in the PCV7 era serotype 6C makes up the 
majority of invasive serogroup 6 isolates in the USA and has increased in Australia 
[46, 211, 346]. A study from the UK reported a four-fold increase in serotype 6C 
carriage in the PCV7 era, due to one genetic lineage, CC395 [187]. By contrast, in 
Germany, the prevalence of serotype 6C has remained low throughout the period of 
PCV7, PCV10, and PCV13 use [313]. Preliminary results concerning PCV13 
indicate that it may provide cross-protection against serotypes 6C and 6D, and that 
PCV7 may offer cross-protection against serotype 6D [58, 59, 202]. Similarly 
interesting from a prevention standpoint is that the epidemiology of newly defined 
serotypes may differ from the previously known ones, as suggested by a South 
African study, which showed that serotype 6C seems more prone to cause 
meningitis than 6A [83]. 
 
Other newly described serotypes from other serogroups may also be present among 
the invasive pneumococci in Finland. Preliminary testing of a monoclonal antibody 
based serotyping scheme [341] indicated the presence of an 11E isolate 
(Unpublished, Siira et al.). This serotype is not discernible by either mPCR or the 
Quellung reaction and would currently be serotyped as 11A. Taken together, all 
these findings indicate that the newly described serotypes have been present in the 
pneumococcal population for a long time, but their clinical significance may become 
apparent only when the use of serotype-specific interventions, e.g. serotype-
dependent vaccines, exercise selection pressure on the pneumococcal population. 
6.2.2 Serogroup 19 
Novel and aberrant serotypes, for which the molecular and phenotypic serotyping 
results are not in agreement, have been described in the advent of new serotyping 
Discussion 
 
 
 
THL — Research 119/2014 81 Clonality of Steptococcus pneumoniae in relation to antimicrobial resistance in Finland 
 
methods. In 2009, a serotype 19F isolate produced a serotype 19A specific PCR 
amplicon. This discovery led to development of the improved 19A specific 
oligonucleotide primers designed at the CDC [258] that were used in the current 
study. Following the implementation of the mPCR-based serotyping protocol into 
continuous use at THL, Helsinki, a discrepancy between the results obtained by 
mPCR and Quellung was discovered. The isolate in question was serotype 19A by 
Quellung but had produced a serotype 19F amplicon in mPCR. The isolate did not 
produce any amplicon with the 19A specific oligonucleotide primers. As a 
precaution, all isolates that produced 19F-specific mPCR results were 
retrospectively and subsequently subtyped by Quellung (Figure 13), and one further 
discrepancy was discovered. The two isolates producing discrepant serotyping 
results by mPCR and Quellung each had novel genotypes, ST8025 and ST8026, 
with four shared alleles. The closest matches for these isolates in the MLST database 
were serotype 19A, 19F, and 10A isolates [227]. 
 
The capsular polysaccharide synthesis loci of serotype 19A and serotype 19F are 
very similar. It has been proposed that differences in one gene, wzy (formerly cpsI), 
give rise to the two different serotypes [220]. This gene encodes the Wzy 
polymerase that links oligosaccharide repeat units to form lipid-linked capsular 
polysaccharides. Wzy determines the serotype by facilitating different types of 
bonds between the otherwise identical oligosaccharide repeat units in the capsules of 
serotypes 19A and 19F [23, 220]. The nucleotide identity between wzy of serotype 
19A and serotype 19F is 78.5%. The amino acid identity between the two Wzy 
proteins is 80.7% [220, 240, 258]. The wzy gene in the two Finnish isolates that gave 
discrepant results by mPCR and Quellung showed 92-93% nucleotide identity with 
the serotype 19F wzy sequences in the GenBank database and 80% identity with the 
serotype 19A wzy sequences, which explains the amplification with the 19F-specific 
wzy primers. 
 
As with, serogroup 6, serogroup 19 is interesting from a PCV perspective, since 19F 
is included in all available vaccines, but 19A is covered only by PCV13. As 
mentioned previously, serotype 19A is a frequently observed replacement serotype 
following PCV7 use [212]. Several genotypes connected with serogroup 19 have 
undergone capsular switching, which illustrates the plasticity of these strains [154, 
227]. At least one serotype 19A vaccine escape recombinant has been identified [37]. 
It has been suggested that PCV7 may have a lower effectiveness against serotype 
19F than against the other vaccine serotypes [184] and this serogroup warrants 
careful surveillance, regardless of the vaccine in use.  
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6.3 Validation of the mPCR based serotyping scheme 
Serotype deduction based on the pneumococcal genotype has recently gained ground. 
Although indirect, the methods appear to be reliable and precise, especially if 
combined with phenotypic methods when needed. In recent years, a variety of 
molecular methods that rely on the cps locus for the deduction of pneumococcal 
serotypes have been described [20, 87, 167, 168, 240, 306]. The mPCR based 
serotyping scheme originally developed at the CDC has been modified in different 
ways for use, not only to better suit the invasive pneumococci in Finland, but also in 
several other countries or areas, such as Alaska [210], Belgium [159], Brazil [76], 
Italy [15], and South-Saharan Africa [218]. The flexibility to combine the 
oligonucleotide primers used for amplification in several ways is important, as it 
allows the modification of a scheme according to the serotype distribution of the 
material to be serotyped. The serotype distribution may vary because samples 
originate from different geographical regions of the world, or from colonising or 
invasive isolates. PCR-based serotyping is usually less expensive than traditional 
serotyping, because the reagents used for mPCR are generally available in 
laboratories and are inexpensive compared to antisera. The most useful and cost-
effective mPCR-based serotyping scheme is set up according to the regional 
serotype distribution, when it is known. When setting up an mPCR-based serotyping 
scheme, the size of the amplicons should be taken into account, as they must be of 
sufficiently different sizes to facilitate visual interpretation. Careful handling of 
samples is essential in mPCR-based serotyping schemes, as well as the use of 
appropriate negative controls at every stage of the serotyping process. Facilities 
suitable for PCR work are also crucial and pure cultures must be used for DNA 
extraction for the results to be reliable. The senisitivity of DNA-based methods is 
illustrated by a false positive serotype 14 amplicon that was discovered during the 
validation process. It is likely that this was caused by is a mix up of isolates or 
contamination at the DNA extraction level. Appropriate negative control practices 
help to prevent problems associated with contamination. The oligonucleotide 
primers are not completely serotype specific; some amplify the same size products 
in all serotypes of a serogroup, such as the primers for serogroup 18. Other primers 
recognise distinct serotypes that share sequence similarity, such as the primers that 
amplify serotypes 7B, 7C, and 40 [240]. For accurate serotype deduction, 
complementary phenotypic methods are needed for the subtyping and confirmation 
of the serotypes that are not distinguishable due to this kind of primer cross-
reactivity, or those serotypes that are not included in any mPCR. Phenotypic 
serotyping remains the most reliable way to discover possible problems with DNA-
based serotyping schemes, as described above in the case of serogroup 19.  
 
One of the benefits of mPCR-based serotype deduction is that isolates can be 
handled in bulk when isolating DNA and performing mPCRs. This reduces the 
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required hands-on time per sample. More than 85% of the invasive pneumococci 
isolated in Finland can be identified either fully or to the serogroup level in the first 
two mPCRs meaning that the hands-on time per isolate is reasonable. The single 
disadvantage when handling samples in bulk is the delay in obtaining serotyping 
results for isolates with rare serotypes identified in mPCRs 5 and 6. The delay is 
particularly noticeable if only full mPCR runs are performed. Schemes that include 
detection of cpsA, such as the mPCR-based serotyping protocol set up in this study, 
have the added benefit of confirming the presence of the cps genes. This allows for 
circumvention of downregulated capsule production, which can sometimes be 
problematic when employing phenotypic methods [278]. Possible untypical cps loci 
will not be detected, however, as the oligonucleotide primers may not be able to 
attach to the DNA. Because of the indirect nature of the mPCR-based serotyping 
schemes, it may be beneficial to verify a subset of the results by phenotypic methods, 
such as Quellung, to make sure the results are in harmony. The reliable 
interpretation of serotyping reactions by the Quellung reaction requires experience 
and the regular application of these skills.  
 
6.4 Antimicrobial resistance and macrolide-resistance 
determinants  
The proportion of isolates non-susceptible to penicillin or erythromycin increased 
significantly over the ten year period. The proportion of penicillin-non-susceptible 
isolates reached nearly 22% in 2011, i.e. the increase was four-fold compared to the 
years 1999 to 2000 [251]. The proportion of penicillin-non-susceptible isolates 
(MIC ≥0.12 mg/L) is higher in Finland than in several other countries. After PCV7 
implementation in Italy, non-susceptibility was 14.4% in 2006-2010 [107]. Similarly, 
the penicillin-non-susceptibility in Finland is very high compared to Sweden, where 
it was only 3.1% in 2007-2011 [91]. In the whole ten year period, especially the 
proportion of intermediately penicillin-resistant isolates was higher in Finland than 
in the other Nordic countries [91]. In Italy in 2006-2010, the proportion of 
penicillin-resistant isolates (MIC ≥4 mg/L) was 1.3% [107], which is higher than 
among the Finnish isolates during the same time. However, in stark contrast, the 
proportion of isolates with penicillin MICs ≥2 mg/L is higher in Finland than in the 
neighbouring country Sweden, where it was only 1.6% in 2007-2011 [91]. 
 
In the first five years of the ten year study period, the proportion of isolates non-
susceptibile to erythromycin increased from 16% to 28% among the invasive 
isolates. Compared to the years 1999 to 2000, the increase was four-fold [251]. Over 
the last five years of the ten year period, the non-susceptibility to erythromycin 
remained high but stable at 26.6%, suggesting that the increase observed in the first 
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five years of the study period levelled off, even though high levels of non-
susceptibility were sustained. 
 
Globally, the highest erythromycin-resistance prevalence is found in the Far East, 
where it was as high as 80% in 2001 to 2004 in a study that included both invasive 
and non-invasive isolates [101]. While the non-susceptibility of invasive isolates is 
much lower in Finland, it is again worryingly high compared to the other Nordic 
countries Denmark, Iceland, Norway, and Sweden. For example, in Sweden, the 
erythromycin-non-susceptibility was 4.8% in 2007-2011 [91]. The situation in 
Finland is more comparable to that in Southern Europe [91]. Definitions of high 
erythromycin MICs vary from ≥32 to 120 mg/L. More than half of the 
erythromycin-non-susceptible invasive isolates from 2007 to 2011 have an 
erythromycin MIC ≥64 mg/L; this is likely to be clinically important and may lead 
to treatment failures [190, 291]. Even if the clinical significance of non-
susceptibility is still debated, it seems clear that non-susceptibility allows isolates to 
proliferate under antimicrobial selection pressure and may give them the opportunity 
to develop full resistance through recombination. Similar to non-susceptibility levels 
to penicillin and erythromycin, antimicrobial consumption is higher in Finland than 
in other Nordic countries, according to a European study [91, 268]. The Nordic 
countries may have been able to keep their resistance and non-susceptibility levels 
low at least partly thanks to conservative antimicrobial prescription policies, which 
help lower the antimicrobial selection pressure in the community [268, 320]. 
Resistance prevalence and high antimicrobial use may lead to a vicious circle, where 
each circumstance feeds the increase of the other. 
 
Th proportion of ceftriaxone-non-susceptible pneumococci remained fairly low 
among the invasive isolates in Finland during the whole study period. The main 
reason for this is most likely that the proportion of fully penicillin-resistant 
pneumococci is still relatively low. Ceftriaxone-resistance is more common where 
highly penicillin-resistant isolates are abundant [94]. In countries with high 
penicillin-resistance prevalence, such as in Taiwan and Spain, pneumococcal non-
susceptibility to ceftriaxone is reported to be 7-9% [50, 310], while in countries with 
a lower penicillin-resistance prevalence, such as in Italy, Hungary, and Portugal, the 
respective proportion is around or below 1% [78, 116, 217]. The relationship 
between penicillin- and ceftriaxone-non-susceptibility is not always a simple one. In 
Spain, the ceftriaxone-non-susceptibility decreased, although the penicillin-non-
susceptibility increased from 1994 to 2004 [78]. 
 
The proportion of multidrug-resistant isolates remained stable among the invasive 
pneumococci over the ten year study period, although both penicillin- and 
erythromycin-non-susceptibility increased. Multidrug-resistance was defined as non-
susceptibility to penicillin, erythromycin, and tetracycline, and the slight decrease in 
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tetracycline-non-susceptibility seen during 2002-2011 may have tempered the 
multidrug-resistance proportion. The stability of the multidrug-resistance prevalence 
is a more hopeful situation than for example in the USA, where the rate of growth of 
multidrug-resistance in respiratory tract infections in 1992 to 2001 was higher than 
that of single antibiotic resistance [207]. In the PCV7 era the multidrug-resistance 
has decreased in the USA [291]. In general, the higher the resistance to 
erythromycin or penicillin among pneumococci, the higher the prevalence of 
multidrug-resistance. For example in the USA, multidrug-resistance proportions 
range from 9% to 25% by region and seems to correspond with the proportion of 
penicillin- and erythromycin-non-susceptibility [63, 155]. It is worth noting, 
however, that the specimen types in the aforementioned US studies also included 
non-invasive pneumococci. 
 
Direct comparisons of antimicrobial resistance percentages between studies are not 
necessarily straightforward, as the proportions may be affected by the time-period, 
the use of PCVs, and the breakpoints used, as well as the isolate inclusion criteria. 
Further, the lack of a uniform definition of pneumococcal multidrug-resistance also 
makes comparison difficult. 
 
It has been put forth that a subset of non-invasive isolates should be studied for 
comprehensive surveillance of resistance, as the same pneumococcal isolates are 
able to cause both invasive and non-invasive disease [175]. The Finnish Study 
Group for Antimicrobial Resistance (FiRe) monitors the susceptibility of 
pneumococci regardless of the specimen type and they report increasing non-
susceptibility to all examined antimicrobials in 1997-2010 [115]. The non-invasive 
isolates are not regularly serotyped or genotyped, and Publication II of this study, 
focusing on a subset of multidrug-resistant non-invasive isolates, is an attempt to 
broaden the view of the clonality of drug-resistant pneumococci in Finland. The 
study of multidrug-resistant non-invasive isolates showed that highly resistant 
serotype 19A isolates were established in the pneumococcal population in Finland 
already prior to large-scale vaccination. Indeed, three years after the non-invasive 
isolates had been isolated and roughly one year after PCV10 had been included in 
the Finnish national vaccination programme, the first highly resistant invasive 
serotype 19A isolate part of the same genetic lineage was discovered (Publication 
IV). Isolates and characteristics that first appear among non-invasive isolates are 
likely to appear also among the invasive isolates before long. 
The hypothetical PCV7 serotype coverage exceeded 80% among both the penicillin- 
and erythromycin-non-susceptible invasive isolates in the years 2002 to 2006, and 
the PCV10 coverage of non-susceptible isolates was even higher in the years 2007 
to 2011. These results indicate that large-scale vaccination that begun in September 
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2010, with the inclusion of PCV10 in the national vaccination programme, probably 
will reduce non-susceptibility rates in the coming years. Indeed, some of the more 
recent antimicrobial susceptibility results presented in this study, as well as by 
others [171], give reason for cautious hope. Over the whole ten year period in the 
current study, the non-susceptibility proportions to penicillin and erythromycin were 
high in the youngest age-groups. However, in 2011, the last year of the study, the 
proportions of isolates non-susceptibile to erythromycin and penicillin were lower 
compared to the previous year among isolates from children aged 2 years or younger. 
Many in this age-group are eligible for vaccination and the slight decline in the 
proportion of resistant isolates may be a consequence of PCV10 use. Future 
surveillance will be able to determine if this decrease continues and to which extent 
it will be reflected in the other age-groups. It is also worth noting that the proportion 
of non-susceptible isolates may vary slightly from one year to the next, as they have 
done before. This emphasises that it is too early to draw definite conclusions about 
the effect of the vaccine on resistance in Finland. Studies from several other 
countries report declining non-susceptibility proportions following PCV use, 
especially when it comes to penicillin [60, 70, 291]. However, other reports suggest 
that the proportion of non-susceptibility to antimicrobial agents has remained stable 
or increased in the PCV era, sometimes even in the age-group eligible for 
vaccination [77, 82, 106, 107, 146, 185, 206, 209]. In the long-term, the effect of 
PCVs on resistance may be a short-lived decrease followed by a rebound [206, 291]. 
The prevalence of antimicrobial resistance may rapidly increase in non-vaccine 
serotype pneumococci [98, 149]. The current study shows that non-susceptible non-
vaccine serotype isolates are already circulating in the pneumococcal population in 
Finland. Although their numbers are low, they may increase in the PCV10 era. 
 
The mef gene was the most frequently discovered macrolide-resistance determinant 
among the studied invasive isolates from 2002 to 2006, which is in agreement with 
the previous studies conducted in Finland [251, 266]. Interestingly, the distribution 
of macrolide-resistance determinants in Finland is more comparable, or even nearly 
identical, to that of North America and Scotland, while differing from much of 
continental Europe [97, 334, 335]. The serotype and susceptibility pattern to 
antimicrobial agents of many of the Finnish mef(A) positive isolates suggest that 
they may be part of one clone. A previous study has shown that a tenth of the 
erythromycin-non-susceptible invasive pneumococci in Finland carry a mutation in 
the ribosome or ribosomal protein that provides macrolide resistance [251]. The 
presence of ribosomal mutations was not investigated among the isolates in this 
study, but 13% of macrolide-non-susceptible pneumococci selected for resistance 
determinant study were not positive for either the known efflux or methylase genes 
and may therefore carry ribosomal mutations. 
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6.5 Genotype clonality and pilus-encoding islets  
It is clear that the most important CCs among the penicillin-resistant invasive 
pneumococcal population in Finland are CC156 and CC320, regardless of whether 
the pre-2008 CLSI breakpoint or the EUCAST breakpoint for penicillin-resistance is 
used. Members of these two CCs are consistently found among the studied isolates 
over the whole ten year period and also feature strongly among the non-invasive 
multidrug-resistant isolates studied.  
6.5.1 Clonal complex 156 
The largest single CC in the MLST database, CC156, has grown to include several 
previous independent CCs in recent years [227]. This is illustrated by the fact that 
CC156 now also covers CC90 and CC138, which were identified among the 
genotyped isolates of Publication I, and were independent CCs at the time of writing 
the original manuscript. Whether or not the eBURST algorithm is successful in its 
goal to group together only STs descended from a common ancestor stain has been 
questioned, especially when it comes to CC156 [221]. The pneumococcus is 
unrestrained in donating and incorporating DNA [67, 337], and intraclonal variants 
have also been shown to have differing invasive disease potential [36]. CC156 
contains isolates that are so dissimilar that they may not share any alleles in the 
seven sequenced housekeeping gene loci [75, 227]. More thorough genotyping 
methods that include up to 96 different loci are able to distinguish ten different 
lineages (a-j) within CC156. The discovery of the fairly rare genotype, ST4945, has 
been pinpointed as the culprit for merging previous CCs, yet analysis clearly 
indicated that this ST belongs to lineage h within CC156 [221]. The genotypes 
identified in the Finnish penicillin-resistant material are mainly concentrated within 
the lineage termed i. This is the lineage which includes the predicted primary CC 
founder ST156. This CC and its predicted primary founder PMEN3 Spain9VST156 
are important in several other countries as well. Close to half of the penicillin-non-
susceptible isolates in Poland in the years 2003 to 2005 and in Sweden in 2003 were 
related to PMEN3 Spain9VST156 [273, 284]. A double locus variant of the PMEN 
clone, ST143, is important both in Finland and in Poland [274]. CC156 is also 
strongly represented among the intermediately but not fully penicillin-resistant 
isolates studied. ST671 was the most frequent ST among the penicillin-intermediate 
isolates. This underlines the different ST distribution compared to the penicillin-
resistant isolates, where the most frequent genotype was ST156. In addition, ST671 
among the intermediate, ST143 among the fully resistant isolates, and ST2916 found 
in both groups, as well as several other CC156 isolates, display non-susceptibility to 
a greater number of antimicrobial agents than the primary founder strain PMEN3 
Spain9VST156. 
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6.5.2 Clonal complex 320 
Among the genetic lineages and serotypes discovered in the non-invasive isolate 
collection (Publication II), CC320 and serogroup 19 dominates, covering two thirds 
of all studied isolates. This CC also has a strong presence among the invasive 
penicillin-resistant isolates (Publications I and IV). The CC320 isolates are related to 
previously known drug-resistant serogroup 19 isolates, such as the global PMEN14 
Taiwan19FST236 clone [204]. CC320 isolates often are multidrug-resistant and 
display high penicillin MICs [291], and this may explain their near absence among 
the intermediate but not fully resistant isolates. The isolates carrying double 
macrolide-resistance determinants in this study were all part of CC320 (Publications 
I and II). The members of this genetic lineage also tend to carry both pilus-encoding 
islets, which may give them a competitive advantage in colonisation, and through 
that in opportunities to cause disease [18, 230]. CC320 is implicated in the rise of 
multidrug-resistance following large-scale use of PCV7 in the USA, Spain, and 
other countries [8, 21, 256]. After some years of PCV7 use in the USA, the serotype 
19A prevalence among invasive cases stabilised at a higher level than in the pre-
PCV7 era. However, CC320 continued to increase in proportion among the serotype 
19A isolates, and along with the success of this clone, the multidrug-resistance 
within the serotype increased [21]. In contrast, in Norway, where the antimicrobial 
resistance levels are low, the invasive serotype 19A disease following PCV 
implementation was found to be caused by the success of a penicillin-susceptible 
clone [320]. In some countries, including Finland, as shown in this study, as well as 
Israel, Korea, and Taiwan, members of the CC320 serotype 19A clone were present 
already before or during low PCV use [69, 144, 281]. This finding implies that 
selection pressure from antibiotics is an important factor in the success of the clone. 
It is likely that unless PCV10 provides cross-protection against serotype 19A, this 
clone will be sustained in the PCV10 era in Finland and may impact the multidrug-
resistance situation. Some members of CC320 or serotype 19A display capsular 
switching within serogroup 19 [227] and even outside the serogroup [4, 338]. The 
serotype 19A ST320 clone that has been widely encountered globally appears to 
have evolved from its ancestral clone PMEN14 Taiwan19FST236 through serotype 
switching. Other changes have also taken place in the genome that allow ST320 to 
outcompete the parent strain in colonisation experiments [144]. Compared to 
serotype 19F ST320, the serotype 19A variant carries similar pbp, erm(B), mef(A/E), 
and tetM genes, but has additional mutations in several other genes that are 
connected with antimicrobial resistance or virulence [256]. 
6.5.3 Novel sequence types and other clonal complexes 
As many as four novel ddl genes were found among the subset of invasive isolates 
studied by genotyping. The ddl gene is situated only 783 bp downstream from the 
pbp2b gene and known to be especially prone to variations during the development 
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of penicillin-resistance. Interspecies recombination at the pbp2b locus often occurs 
under selection pressure brought on by the use of penicillin, and the changes in the 
genome often extend through the ddl gene. This so-called gene hitchhiking has been 
described extensively and is the reason for eliminating the locus from some tools for 
the analysis of pneumococcal clonality, as it may distort the relationship between 
strains [89]. 
 
Of the penicillin-resistant isolates genotyped in 2002 to 2006, 16% had STs that 
have to date not been described elsewhere, and at the time of writing the manuscript 
this proportion covered as many as a third of the isolates. An even higher proportion 
was described in a study from Norway, where 42% of the genotyped penicillin-non-
susceptible isolates had a previously unknown genotype [290]. Interestingly, with 
one exception (ST2918), the novel genotypes described among these Finnish 
isolates are multidrug-resistant and many of them are also related to successful 
international clones. The time and place of origin of the novel STs detected in this 
study is unknown. The MLST database relies on the voluntary submission of 
genotyped isolates and is thus unlikely to include all analysed isolates. Furthermore, 
it is probable that a bias towards studying drug-resistant and invasive pneumococci 
is reflected as oversampling in the database material. Genotyping may also not be 
performed by the same frequency everywhere. These considerations combined with 
the limitations of the eBURST algorithm may also affect the assignment of both 
subgroup founders and the predicted primary founder of a CC [75]. For instance, it 
is likely that the true founder of CC156, and of lineage i within it, is the penicillin-
susceptible genotype ST162. However, the algorithm assigns ST156 as the predicted 
primary founder of the CC [293]. ST162 has nearly as many SLVs as ST156, and 
more double and triple locus variants, which places this genotype at the centre of 
CC156 [75]. 
 
While several of the same CCs were present among the intermediately penicillin-
resistant isolates from the year 2005 as among the penicillin-resistant isolates, there 
are marked differences in the distribution of STs within the populations. It is 
interesting to note that several of the PMEN strains, such as PMEN31 
Netherlands3ST180 or PMEN9 England14ST9, identified or related to isolates among 
the intermediately resistant isolates are susceptible to penicillin. Serotypes, such as 3, 
6A, 9N, and 18C, which rarely exhibit penicillin-non-susceptibility, are represented 
by single or a couple of isolates. These observations indicate recombination of non-
susceptible isolates, in addition to the presence of clonal non-susceptibility. These 
kinds of isolates may become significant especially in the PCV10 era as several of 
them are not covered by the vaccine. Antimicrobial resistance determinants such as 
the altered pbp genes required for penicillin-resistance have been introduced through 
horizontal gene transfer after the CCs have been established. This is illustrated by 
the fact that the CCs also contain susceptible strains [337]. Taken together, this 
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indicates that established and successful clones may acquire resistance determinants 
and survive in a setting with antimicrobial selection pressure. 
 
Although the serotype is not a completely reliable clonal marker, the increasing 
levels of penicillin- and erythromycin-non-susceptibility among serotype 14 isolates 
in this study, suggests that clonal expansion may be a driving factor in intermediate 
resistance. Intermediately penicillin-resistant and erythromycin-non-susceptible 
serotype 14 isolates were represented in the material by CC156, CC63, and CC15. 
These are important widely disseminated CCs and CC15 has a high invasive disease 
potential [36, 227], therefore it is likely that they are present among the invasive 
pneumococci in Finland also in the later years. 
 
6.6 Pilus-encoding islets 
Two pneumococcal pili encoded by PI-1 and PI-2 have been described on the 
surface of pneumococci and have been suggested as potential vaccine candidates for 
a multivalent protein vaccine against pneumococcal disease [16, 223]. In a mouse 
model, this pilus provided a competitive advantage over non-piliated pneumococci 
in the nasopharynx, and it has been suggested that this may contribute to the spread 
of the piliated clones [284]. The presence of PI-1 has previously been shown to 
correlate with antimicrobial resistance [2], but no consistent similar association has 
been confirmed for PI-2. However, in a study conducted in Atlanta, Georgia, USA, 
in the PCV7 era, all the PI-2 positive serogroup 19 isolates in CC320 were resistant 
to penicillin, erythromycin, trimethoprim/sulfamethoxazole, tetracycline, and 
chloramphenicol [343]. This resembles the non-susceptibility pattern of the CC320 
isolates from Southern Finland and of the majority of the invasive CC320 isolates 
for the antimicrobial agents tested. Members of CC320 generally carry both PI-1 
and PI-2. 
 
Among the invasive pneumococci, the PI-1 positive genotypes were found in five 
CCs, including CC156 and CC320, discussed above, and in one singleton. Carriage 
of PI-1 has previously been found to associate both with the serotype and the 
genotype, and PI-1 gene prevalence is high among drug-resistant isolates [2, 19, 
223]. In isolates from Portugal, PMEN3 Spain9VST156 is associated with the 
presence of PI-1, regardless of serotype and 61% of the penicillin-non-susceptible 
isolates carried PI-1, while the corresponding figure for susceptible isolates was 
16% [2].  
 
In a Finnish study into non-invasive isolates from the early 1990s, 20% of the 
pneumococci isolated from children with acute otitis media carried the PI-1 genes, 
but the PI-2 genes were not found [308]. In contrast, the large proportion of PI-2 
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positive non-invasive and invasive isolates in this study, which focuses on clonality 
with reference to antimicrobial resistance, may suggest that PI-2 could have spread 
the pneumococcal population in tandem with resistant clones. 
The frequency of PI-1 has reportedly initially decreased since the introduction of 
PCV7, probably because a majority of the PI-1 associated serotypes described so far 
are covered by the available vaccines [19]. Recently it has been reported that PI-1 
re-emerged after a few years of PCV7 use and in some areas it has eventually 
exceeded the pre-vaccination rate [267]. The prevalence of PI-1 reported to be 
approximately 15% to 30% depending on the area and the vaccination programme 
status in the community [1, 222, 267, 279]. On the other hand, reports indicate that 
PI-2 carrying invasive pneumococci have increased following wide use of PCV7, 
partly because of the emergence of piliated serotype 19A isolates [1, 343]. In a large 
study of paediatric isolates from Alabama, USA, the proportion of PI-1, pspA, and 
pspC gene carrying isolates was unaffected by seven years of PCV7 use [64]. 
Overall, 92% of the non-invasive isolates, and 74% (2002-2006) or 100% (2007-
2011) of the invasive isolates genotyped in this study carried the genes for one or 
both pili. Clearly, pilus gene carriage among drug resistant pneumococci in Finland 
is high, which indicates that a potential future vaccine containing pilus proteins 
would be helpful in controlling the spread of these clones.  
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7 Conclusions and future 
considerations 
This study illustrates the importance of surveillance of both clonality and 
antimicrobial resistance. Large-scale interventions, such as the use of PCV10, which 
since September 2010 is part of the Finnish national vaccination programme, 
underlines the importance of ongoing surveillance. The serotyping scheme set up 
and validated in this study will aid in the continued serotype-specific surveillance of 
the invasive pneumococcal population. Studying the pneumococcal population by 
genotyping provides more information about the circulating strains than serotyping 
alone can provide, and will help to determine if the established clones proliferate or 
are replaced by others. 
  
This study shows that several globally disseminated resistant clones, such as 
PMEN3 Spain9VST156, have established themselves in Finland. These clones also 
include the multidrug-resistant serotype 19A clone within CC320 that globally has 
emerged primarily following extensive PCV use. The impact of these clones on the 
antimicrobial resistance following large-scale vaccination in Finland is still unclear. 
However, it is likely, that as they are already well-established, these successful 
resistant clones will be sustained and possibly expand. As seen in this study, clones 
found among non-invasive isolates, are likely to turn up also in the invasive 
population before long. Comprehensive surveillance of clonality in relation to 
antimicrobial resistance should therefore also in the future aim to examine a subset 
of non-invasive isolates. The novel genotypes in this material attest to the 
continuous recombination and diversification of existing resistant clones. 
 
The antimicrobial non-susceptibility and resistance levels in Finland are higher than 
in its neighbouring countries, and increased over the ten year study period 2002-
2011. This is worrying, especially as high non-susceptibility levels may lead to a 
vicious circle, where more antimicrobials are used to treat infections, which in turn 
often leads to higher resistance. In Finland, the proportion of isolates non-
susceptible to penicillin or erythromycin is especially high, covering a fifth and a 
fourth of the invasive isolates from the year 2011, respectively. PCV10 covers the 
majority of the non-susceptible isolates among the invasive isolates, which gives 
hope that the resistance prevalence will be restrained by vaccine use in the coming 
years. However, some non-vaccine serotypes are also present among the non-
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susceptible isolates and these may quickly develop full resistance under selection 
pressure from antimicrobials. 
 
New typing methods and the increasing use of PCVs are likely to bring about the 
discovery of novel serotypes. This study shows that some newly identified serotypes, 
such as 6C and 6D, have been present in the Finnish invasive pneumococcal 
population for several years. This has implications for potential serotype 
replacement following PCV use, as these and previously rare serotypes may 
proliferate when previously successful clones are controlled by vaccines.  
 
To conclude, this study deepens our understanding of the clonality of pneumococci 
in relation to antimicrobial resistance in Finland and illustrates the dynamic nature 
of the pneumococcal population. Due to the years included in this study, the main 
focus is on the pneumococci isolated before extensive PCV use, but future 
monitoring will be able to determine how the population evolves in the PCV era. It 
is essential that the surveillance of both serotype clonality and antimicrobial 
resistance continues in the PCV era. 
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